Systemic glucose availability is a direct fuel for tumor progression. Cancer cells act as “resource hogs,” importing blood glucose at rates up to 100 times higher than normal tissues. This is mediated by overexpression of GLUT1 and GLUT3, which act as rate-limiting factors for glycolytic flux.

This excessive consumption creates a “Tragedy of the Commons” within the tumor microenvironment. While individual cells “resource-hog” to maximize proliferation, this behavior eventually leads to lactate overproduction and TME acidification (pH 6.0–7.0). Interestingly, research suggests that inhibiting GLUT1 can force cells to act more “cooperatively” by reducing individual competitiveness, potentially mitigating this resource-hogging dynamic.

From a therapeutic perspective, the link between glucose and malignancy is clear: because cancer cells are metabolically inflexible and dependent on high-volume glucose, systemic carbohydrate restriction and the pharmacological inhibition of GLUTs—using agents like Phloretin, WZB117, or Fasentin—offer a strategic means to deprive the tumor of its primary energy source and induce metabolic collapse.

Restricting the Supply: The Logic of Carbohydrate Restriction and Keto

Nutrient deprivation serves as a strategic therapeutic adjunct to standard oncology. By restricting carbohydrates, the biochemical vulnerabilities of the Warburg Effect are targeted through two primary mechanisms:

• Biosynthetic Deprivation: Reducing glucose supply restricts the “construction parts”—nucleotides, lipids, and amino acids—required for macromolecular replication. Without these precursors, tumor expansion is stymied.

• NADH Shuttle Saturation: A low-carb/high-fat (Keto-style) environment targets a critical redox bottleneck. In cancer, lactate fermentation is recognized as a secondary redox strategy activated only after the mitochondrial NADH shuttles—the malate-aspartate shuttle (MAS) and the glycerol 3-phosphate shuttle (G3PS)—become saturated. Forcing the cell away from fermentation and back toward mitochondrial use induces severe metabolic stress.

However, a strategic trade-off exists: the “Stealth Mode” risk. Reducing GLUT activity may induce a quiescent (non-proliferative) state, which makes the tumor resistant to conventional chemotherapies that target the cell cycle. This necessitates a precision-timed approach to metabolic therapy.

The “Hostile Neighborhood”: Lactate and Immune Escape

The impact of the Warburg Effect extends into the TME, where lactate serves as a potent signaling ligand rather than a mere waste product.

• Lactate and GPR81: Lactate acts as a ligand for the GPR81 receptor, inducing an “M2 phenotype” in macrophages and inhibiting Natural Killer (NK) cell activity, thereby facilitating Immune Escape.

• Angiogenesis: High lactate levels stabilize HIF-1α, driving new blood vessel growth via VEGF.

• Chemoresistance and Ionic Trapping: The acidic TME (pH 6.0–7.0) creates a phenomenon known as ionic trapping. Weakly basic chemotherapeutic drugs become protonated in the acidic extracellular space, preventing them from crossing the cell membrane and neutralizing their efficacy.

• The Reverse Warburg Effect: This describes a metabolic symbiosis where Cancer-Associated Fibroblasts (CAFs) perform glycolysis and export lactate via MCT4. The cancer cells then “recycle” this lactate, importing it through the MCT1 transporter to use as fuel for OXPHOS, effectively scavenging energy from their own microenvironment.

Conclusion: Strategic Takeaways for Metabolic Management

The Warburg Effect is the cornerstone of modern cancer biology. Understanding the tumor’s metabolic landscape is essential for the transition toward targeted metabolic management.

Critical Strategic Takeaways:

1. Velocity Over Efficiency: The speed of glycolysis, reaching a 200-fold increase, is what enables the rapid biosynthesis required for indefinite growth.

2. Lactate as a Ligand: Lactate is a functional signaling molecule (via GPR81 and MCT1) that orchestrates immune evasion and the “Reverse Warburg” symbiosis.

3. Metabolic Dependencies: Successful therapy must target specific dependencies—inhibiting GLUTs with agents like WZB117 or targeting enzymes like PKM2—while carefully managing the risk of treatment-induced quiescence.

The future of clinical oncology lies in the integration of these metabolic interventions with conventional therapies to effectively strip cancer of its “sweet temptation” and improve long-term clinical outcomes.

Focus: Leukemia, Lymphoma, and Multiple Myeloma

A comprehensive overview of the molecular mechanisms and preclinical evidence that position benzimidazoles as a promising, cost-effective frontier in the fight against blood cancers.

Hematological malignancies are the fourth most common type of cancer and the leading cause of cancer-related deaths, encompassing leukemias, lymphomas, and multiple myeloma. Although numerous therapies are approved, patients frequently develop drug resistance and experience toxic side effects, driving a critical need for novel, safer therapies.

This guide synthesizes current research on the repurposing of anthelmintic benzimidazoles—specifically mebendazole, albendazole, flubendazole, and fenbendazole—as targeted therapies for hematological malignancies. It details the biochemical pathways and molecular mechanisms used to bypass conventional chemotherapy resistance and eliminate cancer stem cells.

Through systematic drug repurposing—which offers a faster, cheaper development track than conventional drug discovery—anthelmintic benzimidazole derivatives (including mebendazole, albendazole, flubendazole, and fenbendazole) have emerged as potent therapeutic candidates for blood cancers. Based on peer-reviewed preclinical and clinical observations, here is how these repurposed compounds target specific hematological malignancies:

1. Acute Myeloid Leukemia (AML): Stem Cell Disruption and Differentiation

AML is characterized by abnormally differentiated hematopoietic cells. Standard cytarabine-based chemotherapies for AML frequently cause severe toxicities, such as myelosuppression and infection. Benzimidazoles target AML by promoting proteasomal degradation of key transcription factors and inducing terminal differentiation. Repurposed benzimidazoles selectively target AML cells through several distinct mechanisms:

Mebendazole (MBZ): The HSP70/c-MYB and GLI Axis

Potently impairs AML cell lines and primary patient samples, inducing mitotic arrest and catastrophe while exhibiting low toxicity toward healthy cord blood-derived cells and peripheral blood mononuclear cells.

MBZ interferes with AML cell survival by targeting the protein-folding machinery, specifically the Heat Shock Protein 70 (HSP70) chaperone system. MBZ disrupts leukemia progression and prolongs in vivo survival by targeting two major transcriptional pathways:

• c-MYB Degradation Pathway:

The transcription factor c-MYB drives oncogene expression in AML, especially in mixed lineage leukemia (MLL)-fusion gene cases.

1. MBZ blocks the HSP70 chaperone system.

2. This blockade inhibits the proper folding of the transcription factor c-MYB (crucial for MLL-fusion gene expression and stem cell self-renewal).

3. Unfolded c-MYB undergoes proteasomal degradation.

4. Result: Reduced colony formation and impaired leukemia progression with negligible impact on normal CD34+ cord blood cells.

• GLI1/2 Degradation:

GLI transcription factors sustain chemotherapy-resistant leukemia-initiating cells.

• MBZ inhibits both HSP70 and HSP90 chaperone activities.

• This leads to the proteasomal degradation of GLI1 and GLI2 transcription factors (effectors of the Hedgehog pathway).

• Targeting GLI eliminates leukemia-initiating cells responsible for chemotherapy resistance and tumor relapse.

Albendazole (ABZ): The KLF4-DPYSL2A Axis

Functions as a non-toxic candidate for differentiation therapy. Unlike traditional cytotoxic chemotherapy, ABZ functions via differentiation therapy in non-APL AML. This action forces non-acute promyelocytic leukemia (non-APL) AML cells to differentiate into mature monocytes. It demonstrates wide anti-leukemic efficacy across multiple AML subtypes with negligible toxicity to normal bone marrow cells

• Mechanism: ABZ stimulates the Krüppel-like factor 4 (KLF4) – dihydropyrimidinase-like 2A (DPYSL2A) axis.

• Outcome: This axis triggers the differentiation of malignant blasts into mature monocytes, effectively clearing the tumor bulk through maturation.

Flubendazole (FLBZ) and Fenbendazole (FBZ): Tubulin and Granulocytes

Induces leukemia cell death at nanomolar concentrations. FLBZ disrupts tubulin polymerization by binding to a site distinct from the conventional chemotherapy drug vinblastine. As a result, vinblastine-resistant cells remain fully sensitive to FLBZ, and combining the two drugs yields synergistic tumor growth delay in vivo.

• FLBZ: Binds to tubulin at a site distinct from vinblastine. This allows FLBZ to remain effective in cells that have developed resistance to standard Vinca alkaloids.

• FBZ: Induces terminal maturation of HL60 cells into granulocytes (confirmed by nitroblue tetrazolium reduction assays). FBZ shows 14.5-fold higher selectivity for leukemia cells than for human bone marrow stem cells.

2. Acute Lymphoblastic Leukemia (ALL) and Chronic Myeloid Leukemia (CML)

T-cell acute lymphoblastic leukemia (T-ALL) represents a significant fraction of pediatric and adult ALL cases, but conventional chemotherapy frequently results in high relapse rates. Benzimidazoles address lymphoid and myeloid malignancies by suppressing proliferative signaling and overcoming gatekeeper mutations.

Acute Lymphoblastic Leukemia (ALL)

MBZ targets T-ALL by suppressing the Notch1 signaling pathway, which is typically overactivated in these malignancies. Dose-dependently suppresses the proliferation of both standard CCRF-CEM cells and chemoresistant CEM/C1 cells

• Downstream Targets: Treatment with MBZ reduces Notch1 downstream targets, specifically c-Myc and Hes1.

• Cellular Impact: Induction of G2/M phase cell cycle arrest and elevated Caspase 3/7 activity, even in chemoresistant T-ALL derivatives (e.g., CEM/C1).

Chronic Myeloid Leukemia (CML)

CML treatment often fails due to the T315I gatekeeper mutation in ABL1.

• Synergy with TKIs: MBZ synergizes with Tyrosine Kinase Inhibitors (TKIs) like imatinib and dasatinib to disrupt the cell cycle in resistant K562 cell lines.

• MicroRNA Modulation: MBZ modulates the miR-150-5p / MYB axis. By inactivating the proto-oncogene MYB, MBZ reduces cell cycle progression and induces apoptosis in CML cells.

3. Multiple Myeloma (MM): Bypassing Efflux and Stem-like Cells

Multiple myeloma cells frequently develop acquired resistance to standard proteasome inhibitors and corticosteroids through successive treatments. Multiple Myeloma is often marked by relapse due to this acquired drug resistance, frequently mediated by P-glycoprotein (P-gp) or ALDH+ stem-like cells.

• Mebendazole (MBZ): Overcomes resistance by targeting the USP5/c-Maf axis 24. Upregulation of the transcription factor c-Maf frequently drives myeloma cell proliferation 24. MBZ suppresses the deubiquitinase USP5, triggering the proteasomal degradation of c-Maf and inducing apoptosis 24. MBZ acts synergistically when combined with the chemotherapy drug daunorubicin or the USP5 inhibitor WP1130 24.

• Albendazole (ABZ): Blocks MM cell proliferation in vitro and in vivo by inhibiting the NF-κB pathway (specifically decreasing p65 and phospho-p65 levels) 2526. This signaling blockade allows ABZ to eliminate ALDH1+ multiple myeloma stem-like cells (MMSCs), successfully re-sensitizing resistant cells to the proteasome inhibitor bortezomib 2526.

• Flubendazole (FLBZ): MM cells commonly develop resistance to standard Vinca alkaloids (vincristine, vinblastine) by upregulating the P-glycoprotein (P-gp) efflux pump. Because FLBZ inhibits tubulin polymerization through a site distinct from Vinca alkaloids, its cytotoxicity is unaffected by P-gp overexpression, successfully inducing cell death in vinblastine-resistant myeloma cells and delaying tumor growth in vivo.

4. Lymphomas: Novel Conjugates and Synergies

Repurposed benzimidazoles have demonstrated unique chemical, cellular, and clinical efficacy against aggressive lymphomas.

• Diffuse Large B-Cell Lymphoma (DLBCL) Regression: A published clinical case study reports an 83-year-old male DLBCL patient who refused standard chemotherapy 30. After self-administering fenbendazole, successive PET/CT scans revealed notable interval disease regression with no new lesions emerging.

Lymphoma research highlights the potential for benzimidazoles to act as both standalone agents and metabolic synergists.

• Fenbendazole (FBZ) Synergy: FBZ demonstrates significant tumor regression when combined with dietary vitamin supplementation. In SCID mouse models, this combination inhibited human lymphoma xenograft growth more effectively than FBZ or vitamins alone.

• Flubendazole (FLBZ) Sensitivity: In large-scale screenings, lymphoid cell lines demonstrated extreme sensitivity to FLBZ, with 82% of leukemia/lymphoma lines and 100% of MM lines displaying an IC_{90} < 1 \mu M.

• Halogenated Derivatives: Benzimidazole-substituted derivatives target integrin \alpha4\beta1. Fluoro, iodo, chloro, and bromo derivatives are being explored as high-affinity ligands for both therapy and radiodiagnostic applications.

• Zinc Phthalocyanine Derivatives: These substituted benzimidazoles exert cytotoxicity in B-cell lymphoma via minor groove binding and intercalation between DNA bases.

  ---

⚠️ A Key Safety Paradox: Spindle Poisoning and LOH

While these compounds are highly effective, researchers highlight a critical genetic caution regarding albendazole (ABZ). Because ABZ acts as a potent spindle poison, even low doses accelerate mammalian chromosomal missegregation and induce Loss of Heterozygosity (LOH). In vivo testing in Msh2-heterozygous mice (a model for Lynch Syndrome) showed that continuous ABZ administration significantly increased the formation of mismatch repair-deficient crypt foci. This suggests that while ABZ is highly cytotoxic to cancer cells, its spindle-disrupting nature could theoretically predispose healthy, haploinsufficient tissue to genomic instability or tumor progression, underlining the need to carefully monitor genetic contexts during clinical translation.

Source:

Deworming to Cancer Therapy: Benzimidazoles in Hematological Malignancies.

Cancers 2024, 16, 3454. https://doi.org/10.3390/cancers16203454

https://www.mdpi.com/2072-6694/16/20/3454

Scientists built a microscopic particle that delivers fenbendazole—an inexpensive anti-worm medicine—directly into a bladder tumor. When a doctor shines a near-infrared light on it, the particle heats up and releases the drug. Together, the heat and the drug push the cancer cells into a built-in self-destruct process that depends on iron (called ferroptosis), and they also wake up the body’s immune system to attack the tumor. In mice, this shrank the tumors. Important: it was tested only in lab-grown cells and mice—never in people—and it requires a special laser, so it is not yet a treatment available at your local hospital.

Bladder cancer is a relentless adversary. Among the most common malignancies of the urinary system, its defining trait is not just its aggression, but its stubbornness; it carries a staggering recurrence rate that forces patients into a grueling cycle of surgeries and intravesical therapies. For decades, the standard of care has relied on localized treatments like the BCG vaccine or traditional chemotherapy, but many tumors eventually learn to evade these defenses.

However, the bladder’s unique anatomy offers a rare opportunity. As a “hollow organ,” it can serve as a biological reaction chamber—a place where medicine can be “clamped” and concentrated without the collateral damage of systemic treatment. Now, a study published in Advanced Science has unveiled a high-tech “triple-threat” nanoplatform that transforms a common veterinary drug into a precision-guided weapon, using targeted light and “iron death” to not only kill tumors but to train the immune system to hunt them down.

The Solubility Paradox: From Vet Clinics to Nano-Medicine

At the center of this breakthrough is Fenbendazole (FBZ). In veterinary medicine, it is a humble anthelmintic—a common dewormer. In oncology, however, FBZ has long been a “hidden gem” with potent anti-tumor properties. The problem? It is pathologically hydrophobic. Because it refuses to dissolve in water, it has been nearly impossible to deliver effectively to human patients.

To solve this, researchers utilized a “molecular heat-shield” made of bovine serum albumin (BSA). By using thermally induced unfolding, the team successfully encapsulated the hydrophobic dewormer inside a water-soluble protein shell. “FBZ exhibits multiple anti-tumor characteristics... However, owing to its poor solubility in water, FBZ has not yet been utilized in anti-tumor research,” the researchers noted, highlighting how nanotechnology finally unlocked a drug that had been sidelined for years by its own chemistry.

Rusting the Cancer from Within

Traditional chemotherapy typically relies on apoptosis, a form of “cell suicide” that many advanced cancers have evolved to ignore. This new platform, known as FBZ@BSA@PDA, bypasses those defenses by triggering ferroptosis—literally, “iron death.”

Ferroptosis is a visceral, biochemical collapse. It involves depleting glutathione (GSH) and downregulating the protective protein GPX4, which essentially strips the cell of its antioxidant armor. Without these defenses, the cell’s fatty membranes begin to “rust” through a process called lipid peroxidation. During RNA sequencing, the researchers discovered a fascinating signature: the treated cells showed gene expression profiles reminiscent of Neutrophil Extracellular Trap (NET) formation. Even though no neutrophils were present, the “ferroptosis stress” was so intense it left behind a unique biochemical echo usually seen in the body’s most violent immune responses.

The study verified this collapse through three critical markers:

• Lethal Lipid Peroxidation (LPO): The accumulation of damaged fats that compromises the cell’s integrity.

• GSH Depletion: The total exhaustion of the cell’s primary defense against oxidative stress.

• Mitochondrial Dysfunction: The structural breakdown of the cell’s internal power plants.

The Light-Driven Ignition Switch

To ensure this “rusting” only occurs within the tumor, the researchers coated the platform in Polydopamine (PDA), a substance that acts as a photothermal agent. When hit with an 808 nm near-infrared laser, the PDA converts light into localized heat.

This isn’t just about burning the cell. In the acidic environment of a tumor, the chemical reactions needed to create cell-killing radicals—known as Fenton reactions—often stall because of the low pH. The laser serves as a “biochemical ignition switch,” using heat to catalyze these reactions and overcome the environmental stalemate. By keeping the bladder within a specific “hyperthermia window” of 43–50 °C, the researchers triggered the drug’s release and amplified its toxicity exactly where the light was pointed, sparing surrounding healthy tissue from thermal damage.

The Accidental Vaccine: Turning Death into a Roadmap

The most profound aspect of this therapy is that it doesn’t just kill the primary tumor; it converts the dying cells into a bespoke, in-situ vaccine through Immunogenic Cell Death (ICD).

As the cancer cells succumb to the combination of ferroptosis and laser heat, they don’t just vanish—they “explode” with molecular “danger signals” called DAMPs. These signals alert the immune system to a threat it had previously ignored. The study observed a precise sequence of immune recruitment: Calreticulin (CRT) was exposed on the cell surface as an “eat me” signal, while HMGB1 was released from the nucleus and ATP was secreted into the surrounding space.

“Mechanistically, it induced lipid peroxidation (LPO), GSH depletion, and mitochondrial dysfunction... This was accompanied by key ICD markers, including calreticulin (CRT) exposure, high mobility group box 1 (HMGB1) release, and adenosine triphosphate (ATP) secretion.”

This molecular flare matures Dendritic Cells (DCs) and activates T-cells, effectively “teaching” the body to recognize and attack any remaining bladder cancer cells.

A Precision Strike in the Biological Chamber

The bladder's “hollow organ” nature allowed researchers to implement a “clamped” delivery strategy. In orthotopic mouse models, researchers instilled the treatment directly into the bladder, then clamped it for 1.5 hours. This ensured the nanoplatform had maximal contact with the bladder wall without entering the bloodstream.

The result was a level of biosafety rarely seen in oncology. While the tumors vanished, the mice showed “no systemic toxicity,” with major organs and blood chemistry remaining entirely healthy. By keeping the fight localized and using light as the trigger, the researchers achieved a precision strike that avoids the “scorched earth” side effects of systemic chemotherapy.

The Future of the Smart Response

The FBZ@BSA@PDA platform suggests a future where cancer treatment is no longer a blunt instrument. By combining the “iron death” of ferroptosis, the catalyst of photothermal heat, and the immune system's long-term memory, we are entering an era of synergistic medicine.

If we can turn a cancer cell’s own destruction into a roadmap for the immune system, we are moving past the era of simply poisoning the body to save it. The question now is: how many other “hidden gems” like Fenbendazole are waiting in the wings, just one nanocarrier away from becoming the next great breakthrough in human health?

A 2026 study published in Advanced Science outlines a breakthrough nanoplatform that combines fenbendazole (FBZ), an inexpensive anti-worm medication, with photothermal therapy (PTT) to treat bladder cancer. By inducing ferroptosis—an iron-dependent form of programmed cell death—and triggering immunogenic cell death (ICD), the strategy activates a robust, dual-immune response against tumors in preclinical models. Here is the source paper that outlined this stack.

Ferroptosis Induction by Fenbendazole Combined With Photothermal Therapy Triggers Dual-ImmunotherapyAgainst Bladder Cancer

Advanced Science, 2026; 13:e74876 Accepted: 28 February 2026

https://doi.org/10.1002/advs.748761 of 13

https://advanced.onlinelibrary.wiley.com/doi/epdf/10.1002/advs.74876

This scientific study investigates a novel combination therapy for non-small cell lung cancer by pairing the antiparasitic drug fenbendazole (FZ) with the metabolic agent diisopropylamine dichloroacetate (DADA). Conducted on immunodeficient mice transplanted with human lung cancer cells, the research demonstrates that these two substances work together to produce a synergistic anti-tumor effect, achieving a 50% rate of complete tumor regression. Beyond merely shrinking tumors, the addition of DADA serves a dual purpose as a hepatoprotective agent, effectively neutralizing the potential liver toxicity typically associated with fenbendazole. The results confirm that this drug pairing is both safe and effective, with no adverse impact on vital organ function or overall survival. Ultimately, the authors propose this well-characterized combination as a promising candidate for drug repurposing and call for further clinical trials to validate its use in human patients.

The Synergistic Equation: FZ & DADA

Synergistic Anticancer Effects of Fenbendazole and Diisopropylamine Dichloroacetate in Lung Cancer Models

Executive Summary

Lung cancer remains the leading cause of cancer-related mortality globally, necessitating the development of novel therapeutic strategies to improve poor prognostic outcomes. Recent research identifies a potent synergistic effect between Fenbendazole (FZ), a veterinary anthelmintic, and Diisopropylamine Dichloroacetate (DADA), a hepatoprotective agent used for chronic liver disease.

The combination therapy (FZ-DADA) demonstrates a multifaceted attack on A549 non-small-cell lung cancer (NSCLC) cells by:

• Inducing Apoptosis: Modulating key proteins (BAX/Bcl2) and activating the caspase cascade.

• Arresting the Cell Cycle: Blocking progression at the G2/M phase.

• Metabolic Reprogramming: Inhibiting glucose uptake and lactate production via the PI3K/AKT signaling pathway.

• Enhancing Safety: Utilizing DADA’s hepatoprotective properties to mitigate potential liver toxicity associated with FZ administration.

In vivo studies using immunodeficient mice show that the FZ-DADA combination significantly reduces tumor volume and achieves a 50% complete regression rate with 100% survival over 60 days, far outperforming single-agent treatments. This data suggests FZ-DADA is a promising candidate for drug repurposing in lung cancer therapy.

Core Components of the Combination Therapy

The research focuses on the “repurposing” of two established compounds to create a synergistic treatment for lung cancer.

Fenbendazole (FZ)

• Primary Use: A broad-spectrum benzimidazole anthelmintic approved for use in animal species.

• Anticancer Mechanism: Acts as a moderate microtubule-destabilizing agent by binding to tubulin. It inhibits glucose uptake and induces mitochondrial translocation of p53.

• Limitations: While effective in reducing tumor size in self-administration cases, it has been linked to drug-induced liver injury.

Diisopropylamine Dichloroacetate (DADA)

• Primary Use: An over-the-counter treatment for chronic liver disease and metabolic disorders (also known as Vitamin B15).

• Anticancer Mechanism: Acts as an inhibitor of pyruvate dehydrogenase kinase (specifically PDK-4), which reduces lactate generation.

• Synergistic Role: DADA is a hepatoprotective agent. Its inclusion in the therapy is designed to reduce the hepatotoxicity of FZ, making the treatment safer for patients with compromised liver function.

Analysis of In Vitro Mechanisms (A549 Cells)

Detailed cellular analysis confirms that the combination of FZ and DADA is more effective than either drug used in isolation.

1. Inhibition of Proliferation and Cytotoxicity

The studies established the half-maximal inhibitory concentration (IC50) for A549 cells at 1 μM for FZ and 5 mM for DADA.

• Synergy Index: The Combination Index (CI) was consistently less than 1.0, which proves a synergistic rather than merely additive effect.

• Optimal Ratio: The most effective results in cellular models were found at a ratio of 1 μM FZ to 5 mM DADA.

2. Induction of Apoptosis

The FZ-DADA combination triggers programmed cell death through several pathways:

• Protein Modulation: The treatment increases the expression of the pro-apoptotic protein BAX (approx. 17-fold) and decreases the anti-apoptotic protein Bcl2 (approx. 4-fold).

• Caspase Activation: The combination significantly upregulates executioner caspases, including Caspase-3 (3.3 to 4 times higher than single agents) and Caspase-7 (12-fold increase).

• PARP Cleavage: The therapy increases cleaved Poly (ADP-ribose) polymerase (PARP) levels by about eightfold, a hallmark of irreversible apoptosis.

• ROS Production: The combination increases mitochondrial reactive oxygen species (ROS), disrupting mitochondrial function and facilitating cell death.

3. Cell Cycle Arrest

FZ-DADA effectively halts cancer cell replication at the G2/M phase. This is achieved by down-regulating critical checkpoints:

• Cyclin A: Decreased approximately 3.5 times compared to single treatments.

• Cyclin E: Decreased approximately 6.6 times compared to single treatments.

4. Metabolic Disruption

Cancer cells rely on metabolic flexibility to survive (the Warburg effect). FZ-DADA disrupts this via the PI3K/AKT pathway:

• Glucose Uptake: The combination significantly reduces 2-deoxyglucose (2-DG) uptake.

• Lactate Production: By inhibiting PDK-4, DADA reduces the synthesis of lactate, a byproduct necessary for cancer cell proliferation.

• Signaling Inhibition: The treatment reduces levels of phosphorylated AKT (pAKT) and PI3K (pPI3K), particularly after 5-7 hours of exposure.

In Vivo Efficacy and Safety (Animal Models)

Studies in immunodeficient BALB/c nude mice transplanted with A549 cells provide evidence of the therapy’s systemic effectiveness.

Antitumor Results

The researchers compared eight groups, including controls (Healthy, Tumor, and Cisplatin) and various FZ-DADA dosage combinations.

Survival and Safety Profiles

• Survival: The combination treatment (Group 8: 40mg/kg FZ + 100mg/kg DADA) resulted in 100% survival over the 60-day study period, compared to only 22.2% in the untreated tumor control group.

• Body Weight: Treated mice maintained or increased body weight, indicating the treatment was well-tolerated.

• Organ Health: Histopathological analysis and blood tests confirmed no significant damage to liver or kidney function:

  • Liver: ALT and AST levels showed no significant hepatocellular damage.

  • Kidney: Urea and creatinine levels remained within normal ranges.

  • Metabolism: Blood sugar and blood lactate levels showed no significant changes among the treatment groups.

Conclusion and Clinical Implications

The synthesis of in vitro and in vivo data demonstrates that the FZ-DADA combination is a robust synergistic strategy against A549 lung cancer cells.

Key Conclusions:

1. Synergistic Superiority: The combination of 40 mg/kg FZ and 100 mg/kg DADA is significantly more effective at inducing tumor regression and extending survival than either agent alone.

2. Multimodal Attack: The therapy simultaneously targets cell structure (microtubules), cell cycle (G2/M arrest), and cell metabolism (PI3K/AKT pathway).

3. Hepatoprotective Benefit: DADA effectively mitigates the liver injury risks typically associated with FZ, allowing for potentially safer long-term administration.

4. Translation Potential: Because both FZ and DADA are well-characterized drugs, this combination is a viable candidate for repurposing as a low-toxicity therapeutic option for Non-Small Cell Lung Cancer (NSCLC).

The researchers conclude that clinical studies are now warranted to validate these findings in human patients.

Sources:

Synergistic anti-tumor effect of fenbendazole and diisopropylamine dichloroacetate in immunodeficient BALB/c nude mice transplanted with A549 lung cancer cells

AME Publishing Company. Transl Lung Cancer Res 2025;14(7):2509-2521 |

Published online Jul 25, 2025. https://dx.doi.org/10.21037/tlcr-2024-1272

https://pmc.ncbi.nlm.nih.gov/articles/PMC12337031/pdf/tlcr-14-07-2509.pdf

Fenbendazole and Diisopropylamine Dichloroacetate Exert Synergistic Anti-cancer Effects by Inducing Apoptosis and Arresting the Cell Cycle in A549 Lung Cancer Cells.

Anticancer Research. 2024 Nov;44(11):4761-4772. doi: 10.21873/anticanres.17302.

https://pubmed.ncbi.nlm.nih.gov/39477286/ https://ar.iiarjournals.org/content/anticanres/44/11/4761.full.pdf

1. Metastatic Triple Negative Breast Cancer

2. Pediatric Glioma

These trials are in various stages of completion. You may want to enter one, or you may just want to follow the results or learn more.

Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer

NCT05318469 · RECRUITING · PHASE1/PHASE2 · posted 2022-04-08 · updated 2026-08-05

https://clinicaltrials.gov/study/NCT05318469

Last Update Posted 2026-08-05, Study Start (Actual) 2023-10-13, Primary Completion (Estimated) 2026-10

This phase II trial studies the side effects and best dose of ivermectin in combination with balstilimab or pembrolizumab and to see how well they work in shrinking tumors in patients with triple negative breast cancer that has spread to other places in the body (metastatic).

A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas

NCT01837862 · ACTIVE_NOT_RECRUITING · PHASE1/PHASE2 · posted 2013-04-23 · updated 2026-08-06, Study Completion (Estimated) 2027-12

https://clinicaltrials.gov/study/NCT01837862

[Active, not recruiting; No longer looking for participants]

This is a study to determine the safety and efficacy of the drug mebendazole when used in combination with standard chemotherapy drugs for the treatment of pediatric brain tumors.

https://pubmed.ncbi.nlm.nih.gov/40509264/

1. The Resistance Challenge

In the world of oncology, ovarian cancer carries a somber and well-earned reputation as the deadliest malignancy of the female reproductive tract. While the medical community has refined the “gold standard” of surgical cytoreduction and chemotherapy, the clinical reality remains heartbreakingly static: approximately 70% of patients with advanced disease will suffer a relapse within just three years. With five-year survival rates stubbornly anchored between 30% and 40%, we are facing a crisis of resistance that demands a departure from traditional drug development.

This urgency has birthed a new era of “medical detective work,” where researchers scour existing pharmacopeias for hidden gems. The latest curiosity? A common veterinary dewormer. A recent study published in BMC Cancer has pulled back the curtain on Fenbendazole, a benzimidazole compound usually reserved for animal parasites, suggesting it may possess the molecular precision needed to dismantle one of human medicine’s most elusive killers.

2. Takeaway #1: The Surprising Efficacy of an Off-Target Hero

Fenbendazole (FBZ) is an “off-target” hero in the truest sense. Long established as a safe, low-cost treatment for parasitic infections in livestock and pets, its jump to human oncology represents the pinnacle of drug repurposing. By focusing on human epithelial ovarian cancer cells (specifically the A2780 and SKOV3 lines), researchers discovered that FBZ inhibits cellular proliferation in a “dose- and time-dependent manner.”

The beauty of repurposing is economic and temporal; because these compounds often come with decades of safety data in other biological systems, they can potentially leapfrog the astronomical costs and high failure rates that plague Phase I development of entirely new molecular entities.

“We found that FBZ inhibited the proliferation and promoted the apoptosis of ovarian cancer cells in a dose-dependent manner... these findings suggest that FBZ has therapeutic potential for the treatment of ovarian cancer.”

3. Orchestrating a “Mitotic Catastrophe”

The microscopy of an FBZ-treated tumor reveals a cellular battlefield. Rather than a simple “off” switch, FBZ induces what scientists call a “mitotic catastrophe.” This specialized form of cell death is triggered by severely dysregulated division.

FBZ acts as a moderate microtubule destabilizing agent, essentially sabotaging the internal scaffold the cell needs to divide. When this scaffold fails, the results are grotesque and lethal for the cancer. Researchers observed:

• Multinucleated Giant Cells: Bloated cells containing multiple nuclei that failed to separate.

• Micronuclei: Genetic fragments scattered throughout the cell like debris.

• Spindle Disorganization: A complete breakdown of the “traffic lanes” required for chromosome migration.

By forcing the cell into this catastrophic state, FBZ mirrors the success of frontline drugs like paclitaxel, but through a unique molecular entry point.

4. Takeaway #3: A Deep Dive into the Genetic Re-Wiring

To understand FBZ's efficacy, we have to look at the transcriptome—the complete set of instructions the cell is reading. The study’s RNA sequencing revealed a massive genetic overhaul, identifying 1,747 differentially expressed genes. This wasn’t a random glitch; FBZ was effectively “scrambling the GPS” of the cancer’s replication cycle and “slashing the brake lines” of its survival pathways.

While the data showed broad impacts on DNA replication and cellular senescence, the team used RT-qPCR to validate a specific set of four genes that serve as the cell cycle’s master controllers. In a precise surgical strike, FBZ significantly shifted their expression:

• CDC25C: Upregulated

• DLGAP5: Upregulated

• TPX2: Upregulated

• CEBPD: Downregulated

5. Takeaway #4: From the Dish to the Living System (In Vivo Success)

The transition from a laboratory petri dish to a complex living system is where most “miracle drugs” fail. However, the FBZ results held firm in mouse xenograft models. Over 21 days, mice with SKOV3-derived tumors received an oral dose of 50 mg/kg daily.

The findings were twofold:

1. Tumor Suppression: Both tumor volume and physical weight were significantly reduced compared with the control group.

2. A Clean Safety Profile: Critically, there was “no significant difference” in the body weight of the mice.

In the high-stakes world of oncology, finding a compound that aggressively targets a tumor without causing systemic “wasting” or toxicity is the “Holy Grail” of early-stage research.

6. Takeaway #5: The Molecular “Stop Sign” (CDK1 and Cyclin B1)

At the molecular level, FBZ places a definitive “Stop” sign in the G2/M phase of the cell cycle. To understand how, imagine the cell’s division machinery as a high-performance engine. For the engine to run, it needs both fuel (Cyclin B1) and a functioning ignition system (the CDK1 protein).

FBZ effectively floods the engine by causing an abnormal accumulation of Cyclin B1, while simultaneously pulling the spark plugs by inactivating (phosphorylating) CDK1. Without a functional Cyclin B1/CDK1 complex, the cell cannot move forward into mitosis.

“Mechanistically, FBZ can inhibit the formation of cyclin B1/CDK1 complexes by promoting CDK1 phosphorylation... The cell cycle is then arrested in G2/M phase, which induces mitotic catastrophe and ultimately leads to tumor cell death.”

7. Conclusion: The Road to Human Trials

We must remain cautiously optimistic; the jump from mice to men is complex. Yet, by identifying the specific genetic rewiring and the “engine-flooding” mechanism of Fenbendazole, researchers have moved this compound from the realm of “veterinary folk medicine” into the light of rigorous precision oncology.

As we look for ways to break the 30% survival ceiling in ovarian cancer, we have to ask: Is the next breakthrough currently sitting on a shelf in a rural farm supply store? If the genetic evidence of the “mitotic catastrophe” is any indication, the future of oncology may be found in the most unconventional of places.

Current Standard of Care and Prognosis Bottlenecks

Epithelial ovarian cancer is the deadliest gynecological malignancy of the female reproductive tract. The current standard of care consists of surgical cytoreduction followed by chemotherapy ± maintenance treatment. Despite these treatments, the five-year survival rate of patients with ovarian cancer has steadily remained unchanged at approximately 30–40%. Furthermore, up to 70% of patients with newly diagnosed advanced ovarian cancer will relapse within 3 years, and subsequent chemoresistance frequently leads to treatment failure. Therefore, identifying novel therapeutic strategies to improve patient prognosis remains a major clinical challenge.

Mitotic Catastrophe as an Oncosuppressive Target

Mitotic catastrophe is an oncosuppressive mechanism of cell death that occurs when cell mitosis is dysregulated. It is characterized by distinct morphological features, including multinucleated giant cells, DNA polyploidization, G2/M cycle arrest, and alterations in the microtubule network. Classic, standard-of-care ovarian cancer drugs like paclitaxel kill cancer cells primarily by forcing them into mitotic catastrophe. Preclinical evidence demonstrates that the repurposed benzimidazole compound fenbendazole (FBZ) acts through a highly similar pathway to kill human epithelial ovarian cancer cells.

In Vitro Efficacy of Fenbendazole Against Ovarian Cancer Cells

Preclinical evaluations in human epithelial ovarian cancer lines, A2780 and SKOV3, show that FBZ exerts a robust, dose-dependent anti-tumor effect:

• Inhibiting Cell Proliferation: FBZ inhibits ovarian cancer cell viability in a dose- and time-dependent manner. After 72 hours of treatment, the half-maximal inhibitory concentration ((\text{IC}_{50})) is 0.38 (\mu\text{M}) in A2780 cells and 0.89 (\mu\text{M}) in SKOV3 cells. FBZ also significantly suppresses the colony-forming ability of these cells.

• Promoting Caspase-Dependent Apoptosis: FBZ induces apoptosis in a dose-dependent manner. Western blot analysis shows that FBZ significantly increases cleaved caspase-3 levels and the proapoptotic BAX/BCL-2 ratio. Although FBZ does not directly alter antiapoptotic BCL-2 expression, the increased BAX/BCL-2 ratio destabilizes mitochondrial membrane integrity and promotes cytochrome C release. Pretreatment with the pancaspase inhibitor Z-VAD-FMK partially blocks cell death and restores cell viability, confirming the activation of a caspase-dependent apoptotic cascade.

• Triggering G2/M Arrest and Mitotic Catastrophe: RNA sequencing of SKOV3 cells treated with FBZ reveals 1,747 differentially expressed genes (DEGs) that are heavily enriched in mitosis- and cell cycle-related pathways. In vitro assays confirm that FBZ causes G2/M phase cell cycle arrest, along with spindle disorganization, multinucleated cells, and micronuclei formation.

• CDK1 Inactivation and Cyclin B1 Accumulation: Mechanistically, FBZ increases the phosphorylation of CDK1 (p-CDK1), which inactivates the cyclin B1/CDK1 complex required for proper mitotic transition. This inactivates cell division, causing abnormal accumulation of cyclin B1 and arresting the cell cycle at the G2/M transition, ultimately driving cells into mitotic catastrophe.

In Vivo Tumor Growth Inhibition

To validate these molecular mechanisms, researchers evaluated oral FBZ in a mouse xenograft model where female BALB/c nude mice were subcutaneously injected with SKOV3 cells.

• Tumor Suppression: Oral FBZ at 50 mg/kg/day for 21 days significantly decreased both tumor volume and final tumor weight compared with the vehicle control group.

• Toxicity and Safety Profile: Body weight did not differ significantly between FBZ-treated mice and control mice, indicating the treatment was well tolerated and did not cause systemic toxicity in vivo.

Transcriptome analysis reveals the anticancer effects of fenbendazole on ovarian cancer: an in vitro and in vivo study

PMCID: PMC11686899 2024 Dec 30;24(1):1593.

doi: 10.1186/s12885-024-13361-9.

https://pmc.ncbi.nlm.nih.gov/articles/PMC11686899/

Any discussion of fenbendazole or other drugs in the benzimidazole class should be based on medical research and evidence—not social media videos or anecdotal claims.

Benzimidazole drugs have been extensively studied, particularly as antiparasitic medications. Mebendazole, for example, has been used safely in humans for decades and has a well-established safety profile. Fenbendazole has also been studied extensively in veterinary medicine as an antiparasitic drug. Because of these characteristics, researchers have investigated whether benzimidazole drugs could be repurposed for cancer treatment.

However, it is important to distinguish between scientific interest and proven cancer treatment. Fenbendazole is a veterinary deworming medication and has not been approved for use in humans to treat cancer. Evidence that it can safely and effectively treat cancer in humans remains insufficient.

Two important points to remember

1. Absorption matters.
Fenbendazole has very low water solubility, which can affect how well the body absorbs it. Its absorption may vary depending on factors such as formulation and what is present in the gastrointestinal tract. This does not mean that simply combining it with other substances makes it an effective cancer treatment.

2. More is not necessarily better.
With any drug, dose matters. Increasing the dose does not automatically make a medication more effective and can increase the risk of adverse effects or toxicity. A dose that is safe in one context may not be safe in another.

Mebendazole and fenbendazole should also not be treated as interchangeable simply because they belong to the same chemical class. Mebendazole is an antiparasitic medication used in humans, while fenbendazole is primarily a veterinary medication.

Fenbendazole has attracted considerable attention because it is inexpensive and widely available for veterinary use. Anecdotal reports from people using it for cancer continue to circulate online, but anecdotes are not a substitute for controlled clinical evidence. Laboratory and animal findings can provide useful leads for research, but they do not establish that a treatment is safe or effective in humans.

For people who lack access to cancer care or cannot afford conventional treatment, the appeal of inexpensive alternatives is understandable. However, limited access to medical care makes it even more important to separate what is known from what is hoped for. Self-administering an unapproved drug can carry real risks, including unknown dosing, drug interactions, side effects, and delaying treatments that have demonstrated benefits.

Just the facts.

Before taking any medication outside its approved use, learn what the human evidence actually shows. Look for clinical studies, safety data, known drug interactions, and information from qualified medical professionals—not just testimonials or social media posts.

If you are considering fenbendazole or another off-label or alternative treatment, discuss it with your doctor whenever possible. If you disagree with your doctor’s recommendation, seeking a qualified second opinion can be a reasonable next step.

The goal should always be the same: make treatment decisions based on the best available medical evidence, understand the risks, and avoid confusing anecdotal claims with established medical facts.

The fenbendazole scandal was a highly controversial public health event in South Korea that began in late 2019 and intensified throughout 2020. It serves as a representative example of how false and unverified cancer information regarding complementary and alternative medicine (CAM) can rapidly spread and disrupt the cancer information market.

The incident centered around the widespread, unverified belief that fenbendazole—an over-the-counter veterinary dewormer used to treat parasites in dogs—could cure terminal lung cancer. This rumor sparked national confusion, leading to the drug selling out at pharmacies across South Korea as desperate patients rushed to get it.

1. The Origin: Joe Tippens and the “Kitruda” Misunderstanding

The scandal originated with claims made by an American cancer patient, Joe Tippens, who asserted that veterinary fenbendazole had cured his terminal lung cancer. However, public media and online communities largely omitted a critical clinical detail: Tippens was also participating in a clinical trial for Kitruda (an immuno-oncology drug) at the MD Anderson Cancer Center.

The narrative that fenbendazole was a standalone “miracle cure” took root.

2. The South Korean Catalyst: Comedian Kim Chul-min

Although the rumor started in the United States, it became a major social phenomenon in South Korea because of celebrity influence. Kim Chul-min, a beloved Korean comedian suffering from lung cancer, announced on social media in September 2019 that he was taking fenbendazole to treat his illness.

At the beginning of the issue, Korean health authorities and medical experts immediately issued press releases warning the public about severe potential side effects, but desperate patients largely ignored them, focusing instead on Kim’s journey.

The timeline of Kim’s public self-treatment illustrates the tragic trajectory of the scandal:

• September 2019: Kim announced his intention to take fenbendazole.

• September 2020: After a year of self-treatment, Kim publicly declared that the drug was ineffective, announced he was stopping his self-medication, and warned other patients not to take it.

• December 2021: Kim Chul-min sadly passed away from his illness.

3. Media Failures and Fragmented Information

A qualitative study utilizing focus group interviews with 21 lung cancer patients exposed severe systemic failures in how health information was reported by the media.

While patients daily sought general cancer information from dedicated internet communities, they passively encountered the fenbendazole rumor through traditional television news and broadcasts. However, this media coverage was highly fragmented and lacked depth:

• Chemotherapy Omission: An overwhelming majority of interviewed patients believed that Kim Chul-min was treating his cancer exclusively with the dog dewormer. TV headlines heavily sensationalized the dewormer but completely failed to mention that Kim was concurrently undergoing standard hospital chemotherapy.

• Lack of Source Verification: Only a tiny fraction of patients actively cross-checked the original source videos on YouTube to discover that Joe Tippens was also undergoing concurrent immunotherapy. The rest relied on simplified, sensationalized snippets broadcast on television and internet portals.

4. Patient Psychology and the “What If” Factor

The focus groups revealed a profound psychological conflict among cancer patients. While most patients rationally understood that fenbendazole was medically unverified and lacked scientific backing, their terminal diagnoses bred a desperate “what if” hope:

“When I hear a story like someone ate something and recovered … it sparks the hope for ‘what if’. Even with the slightest hope like this, I want to try it.”

This desperation caused patients to actively ignore official medical warnings. Because they felt a lack of guidance on self-care and immune-boosting protocols at home, they took matters into their own hands:

• Subjective Filtering: Patients created their own arbitrary guidelines based on “common sense” or gut feelings to determine if an online rumor was an exaggerated commercial.

• Self-Clinical Testing: Desperate patients used their own bodies as testing grounds, trying the drug and monitoring their own physical reactions to gauge success. For example, one patient in the study noted that they ultimately had to stop taking fenbendazole because it was damaging their liver.

5. The Role of “YouTube Journalism”

The study highlighted that YouTube has evolved into a uniquely powerful, active search channel for patients. While patients initially heard about fenbendazole passively on TV, they immediately turned to YouTube to search for personal testimonials, patient diaries, and alternative opinions.

Because YouTube lacks the strict peer-review or verification of professional medicine, the highly emotional “evidence of experience” shared by other patients often completely overrode the scientific warnings of the medical community.

6. Political and Policy Repercussions

The social chaos and panic surrounding the dewormer were so severe that the fenbendazole scandal was raised during South Korea’s 2020 parliamentary audit of the Ministry of Health and Welfare.

Researchers and policy experts concluded that health authorities must transition away from slow, reactive press releases and instead establish preemptive, user-centered communication networks. The study recommended that governments actively monitor online platforms, collaborate with medical experts to quickly verify trending CAM claims, and work with video platforms to introduce verification labels that help vulnerable patients distinguish expert medical advice from unverified personal anecdotes.

ORIGINAL RESEARCH article:

How cancer patients get fake cancer information: From TV to YouTube, a qualitative study focusing on fenbendazole scandle

Front. Oncol., 27 October 2022

Sec. Cancer Epidemiology and Prevention

Volume 12 - 2022 | https://doi.org/10.3389/fonc.2022.942045

https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.942045/full

https://www.sciencedirect.com/science/article/pii/S2468294222000910?via%3Dihub

Teaching an old dog new tricks: The case of Fenbendazole

https://pubmed.ncbi.nlm.nih.gov/42203321/

Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort

https://www.mdpi.com/1422-0067/23/8/4315

Message from Sonny:

Double Repositioning: Veterinary Antiparasitic to Human Anticancer

https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1795402/full

Management of advanced HR-positive breast cancer using metabolically supported chemotherapy and repurposed drugs: a case report

https://link.springer.com/article/10.1186/s13058-022-01591-3

Mebendazole prevents distant organ metastases in part by decreasing ITGβ4 expression and cancer stemness

https://www.mdpi.com/1422-0067/23/1/519

Flubendazole Plays an Important Anti-Tumor Role in Different Types of Cancers

https://www.canceractive.com/article/repurposing-old-off-patent-drugs-as-new-and-effective-cancer-treatments

Repurposed, off-label drugs as new and effective cancer treatments: Top 25

https://pubmed.ncbi.nlm.nih.gov/36854536/

Redox-mediated Anticancer Activity of Anti-parasitic Drug Fenbendazole in Triple-negative Breast Cancer Cells

https://www.mdpi.com/1420-3049/26/17/5118

Anticancer Effect of Benzimidazole Derivatives, Especially Mebendazole, on Triple-Negative Breast Cancer (TNBC) and Radiotherapy-Resistant TNBC In Vivo and In Vitro

https://pubmed.ncbi.nlm.nih.gov/38131223/

A novel treatment to enhance survival for end-stage triple-negative breast cancer using repurposed veterinary anthelmintics combined with gut‑supporting/immune enhancing molecules

https://link.springer.com/article/10.1007/s11060-024-04654-x

Repurposing mebendazole against triple‑negative breast cancer CNS metastasis

https://www.mdpi.com/2072-6694/15/4/1330

Mebendazole Treatment Disrupts the Transcriptional Activity of Hypoxia-Inducible Factors 1 and 2 in Breast Cancer Cells

https://www.researchsquare.com/article/rs-3915392/v1

Repurposing mebendazole against triple-negative breast cancer leptomeningeal disease

Conclusion

In summary, MBZ was a safe and effective oral agent in an aggressive animal model of TNBC LMD. MBZ may function by selectively targeting migrating tumor cells. These findings align with previous efforts involving MBZ and CNS pathology and further support the drug’s potential utility as an alternative therapy for TNBC LMD.

https://link.springer.com/article/10.1186/s13058-022-01591-3

Mebendazole prevents distant organ metastases in part by decreasing ITGβ4 expression and cancer stemness

https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1596694/full

Fenbendazole induces pyroptosis in breast cancer cells through HK2/caspase-3/GSDME signaling pathway

https://www.mdpi.com/1648-9144/58/9/1239

Antidiabetics, Anthelmintics, Statins, and Beta-Blockers as Co-Adjuvant Drugs in Cancer Therapy

https://www.mdpi.com/2072-6694/14/19/4601

Repurposing of Benzimidazole Anthelmintic Drugs as Cancer Therapeutics

https://www.sciencedirect.com/science/article/pii/S2211383522003999

Benzimidazole and its derivatives as cancer therapeutics: The potential role from traditional to precision medicine

https://pubmed.ncbi.nlm.nih.gov/30196056/

Mebendazole Potentiates Radiation Therapy in Triple-Negative Breast Cancer

https://www.canceractive.com/article/an-offlabel%20drugs%20protocol%20for%20cancer

Building an off-label drugs protocol for cancer?

https://pubmed.ncbi.nlm.nih.gov/39355784/

Anticancer role of flubendazole: Effects and molecular mechanisms (Review)

Flubendazole, an anthelmintic agent with a well-established safety profile, has emerged as a promising anticancer drug, demonstrating efficacy against a spectrum of cancer types over the past decade.

https://pubmed.ncbi.nlm.nih.gov/40605964/

Fenbendazole Case Reports: 3 Stage IV Cancers in Remission (2025 Case Series)

This article is for research and informational purposes only. It does not constitute medical advice and is not a substitute for professional oncology consultation. Always discuss any investigational protocol with your physician. This article was retracted. However, it’s still worth a read. --Retraction Statement: Paper by William Makis, Ilyes Baghli, and Pierrick Martinez entitled “Fenbendazole as an Anticancer Agent? A Case Series of Self-Administration in Three Patients” [Case Rep Oncol. 2025;18:856-863; https://doi.org/10.1159/000546362]

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0345701

Repurposing mebendazole to reprogram oncogenic and tumor-suppressor networks: Multi-cancer insights from ENOX2, MMP2, RASSF1A, WFDC10A and METTL7A

https://www.mdpi.com/1420-3049/31/12/2070

PEG-b-PCL Micelles as Nanocarriers for Poorly Soluble Benzimidazoles: A Comparative Study of Albendazole and Fenbendazole

https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.670804/full

Repositioning of Antiparasitic Drugs for Tumor Treatment

The significant improvement in drug bioavailability when taken with a fatty meal is a critical pharmacokinetic concept, especially for highly lipophilic (fat-soluble) compounds like the benzimidazole class. Because these drugs fall under BCS Class II (low aqueous solubility but high intestinal permeability), they struggle to dissolve in the watery gastrointestinal environment, resulting in very poor absorption under fasted conditions.

Co-administration with dietary fat overcomes this physical barrier in several key ways:

1. Dissolution of Fat-Soluble Compounds

As lipophilic substances, drugs like mebendazole, albendazole, and fenbendazole physically require dietary lipids to dissolve so they can be transported across the intestinal membranes into systemic circulation. Without dietary fat, most of the administered dose remains undissolved in the gut and is excreted. A high-fat meal acts like a micro-emulsifying delivery system, increasing the drug's lipid solubility and maximizing therapeutic absorption.

2. Quantitative Absorption Boosts Across Compounds

The exact impact of a high-fat diet varies by compound, but the boost in therapeutic exposure is highly significant:

• Albendazole (ABZ): In a fasted state, human gastrointestinal absorption of albendazole is exceptionally low—typically less than 1% to 5%. Taking albendazole with a fatty meal increases its absorption up to 5-fold to 6.5-fold in humans and animals.

• Mebendazole (MBZ): Mebendazole’s baseline oral bioavailability in humans is only about 5% to 10% (or up to 17% to 20% depending on the specific formulation). Administering mebendazole with a high-fat meal increases its absorption more than 5-fold. In oncological protocols, taking mebendazole with dietary fat is considered non-optional, as it directly determines whether the drug reaches the systemic, tumor-fighting concentrations required in the bloodstream1.

• Oxfendazole (OFZ): When co-administered with a high-fat meal, oxfendazole exhibits an increase in its peak plasma concentration by 49% and its overall systemic drug exposure (Area Under the Curve, or AUC) by 86%.

• Fenbendazole (FBZ): Preclinical models likewise confirm that administering fenbendazole with food significantly improves its overall intestinal absorption and tissue uptake.

Ultimately, utilizing dietary fat is one of the simplest and most effective clinical methods to prevent these lipophilic repurposed compounds from being wasted in the digestive tract, ensuring they reach active therapeutic levels in the blood.

Sources:

Oral Fenbendazole for Cancer Therapy in Humans and Animals

ANTICANCER RESEARCH 44: 3725-3735 (2024) doi:10.21873/anticanres.17197

Repurposing of Benzimidazole Anthelmintic Drugs as Cancer Therapeutics

Cancers 2022, 14, 4601. https://doi.org/10.3390/cancers14194601

Why Everything You’ve Been Told About Cancer May Be Wrong — And What the Science Actually Shows

Apr 30, 2026 | Adjunctive Cancer Care

https://drpierrekory.com/blog/why-everything-youve-been-told-about-cancer-may-be-wrong-and-what-the-science-actually-shows/

Focus:

• Brain Tumors (Glioblastoma): Using lipid systems capable of crossing the blood-brain barrier to target aggressive, temozolomide-resistant cerebral tumors.

• Colorectal Cancer: Bypassing traditional therapy resistance by localized colonic release.

• Ovarian Cancer: Overcoming systemic administration barriers via nab-nanoparticles and intraperitoneal tumor target designs.

• Hepatocellular Carcinoma: Utilizing liver-selective uptake vectors (such as glucan or chitosan-lipid carriers) to concentrate the active drug directly inside hepatic lesions.

This academic review explores the therapeutic evolution of Albendazole, a traditional medication used to treat global parasitic infections. The authors address a critical pharmacological hurdle: the drug’s low aqueous solubility and oral bioavailability, which currently limit its clinical effectiveness. To overcome these barriers, the text details innovative nanomedicine approaches, such as nanocarriers, lipid systems, and solid dispersions, designed to improve drug absorption and targeting. Beyond its role as an anthelmintic, the source emphasizes the significant potential for drug repurposing, providing evidence that Albendazole can be repositioned as an anticancer agent for treating tumors in the brain, breast, and colon. Ultimately, the paper consolidates recent scientific advances to show how modern delivery systems can maximize the medicinal impact of this versatile compound.

Albendazole Repurposing and Nanomedicine Strategies in Oncology

The clinical development of repurposed therapeutics offers a powerful, fast-tracked route in oncology. Because these compounds are already approved for other indications, their safety, tolerability, and toxicological profiles are well established, dramatically reducing early-stage discovery risks and clinical timelines.

The selected source highlights the anti-parasitic drug albendazole (ABZ) as a premier candidate for cancer repurposing. Preclinical and clinical models demonstrate that albendazole targets multiple hallmark pathways of cancer cell survival and proliferation:

1. Broad-Spectrum Molecular Mechanisms of Repurposed Albendazole

While originally designed to disrupt parasite tubulin, albendazole possesses a highly multi-targeted (polypharmacological) mechanism of action against cancer cells:

• Mitotic Spindle Collapse: Albendazole binds to (\beta)-tubulin to inhibit microtubule polymerization. This structural collapse prevents mitotic spindle assembly, trapping rapidly dividing cancer cells in the G2/M phase of the cell cycle and driving them into intrinsic apoptosis.

• Targeting the RNF20/Eg5 Axis: Albendazole directly downregulates the E3 ubiquitin ligase RNF20, preventing the monoubiquitination and stabilization of the motor protein Eg5. This triggers the proteasomal degradation of Eg5, a critical protein required for proper mitotic spindle assembly.

• AMPK/mTORC1 Blockade: In cholangiocarcinoma, albendazole activates the metabolic sensor AMPK and actively disrupts mTORC1 signaling (by targeting the Raptor-containing complex). This blocks autophagic flux and forces tumor cells into programmed cell death.

• Suppression of STAT3/STAT5 Signaling: In gastric cancer lines, albendazole suppresses the phosphorylation of STAT3 and STAT5, shutting down downstream survival and proliferative signaling.

• SIRT3/ROS Induction in Leukemia: In human leukemia (U937) cells, albendazole triggers SIRT3 knockdown, activating a SIRT3/ROS/p38 MAPK/TTP signaling axis that upregulates tumor necrosis factor-alpha (TNF-(\alpha)) to induce cancer cell death. In other leukemia profiles (K562), it can modulate SIRT3 expression to sensitize cells to target therapies.

• Glucose and Glycolysis Starvation: By downregulating glycolytic pathways, albendazole directly blocks cancer cells from importing and processing energy.

• Anti-Angiogenesis: Albendazole restricts a tumor’s ability to recruit blood vessels by decreasing HIF-1(\alpha) and VEGF levels. In preclinical models, combining albendazole with the VEGF-inhibitor bevacizumab achieved a synergistic reduction in vascular development.

2. The Biopharmaceutical Barrier: Overcoming BCS Class II Status

Despite its high efficacy in laboratory dishes, albendazole’s clinical translation as an oral cancer drug has been severely hindered by its Biopharmaceutics Classification System (BCS) Class II status—meaning it has extremely poor water solubility (41 mg/L) and low oral bioavailability.

To bridge this gap, modern drug-repurposing research is heavily focused on pairing albendazole with nanomedicine-based drug delivery systems to improve systemic absorption and tumor-specific targeting:

• Albumin Nanoparticles (nab-ABZ): Similar to the design of nab-paclitaxel, encapsulating albendazole in bovine serum albumin (BSA) or BSA-polycaprolactone nanoparticles dramatically increases solubility. In ovarian (OVCAR3, SKOV3) and pancreatic (AsPC-1) models, nab-ABZ achieved over 80% cellular uptake and penetrated dense 3D multicellular tumor spheroids without toxicity to healthy cells.

• Chitosan-Coated Nanostructured Lipid Carriers (ABZ-CS-NLCs): Coating lipid carriers with chitosan flips the nanoparticle surface charge to positive (+24.61 mV). This positive charge facilitates a strong electrostatic attraction to the negatively charged membranes of cancer cells, lowering the (\text{IC}_{50}) to 8.89 (\mu\text{M}) in HepG2 liver cancer cells.

• Enteric-Coated Nanosuspensions: By using Kollidon VA64 stabilizers and coating granules with microcrystalline cellulose encapsulated in EUDRACAP, researchers achieved colon-targeted drug release. This delivery system yielded strong localized release (60% colonic release) and outstanding cytotoxic potencies against colorectal lines, with (\text{IC}_{50}) values of 1.18 (\mu\text{M}) and 3.59 (\mu\text{M}) in HCT116 and HT-29 cells.

• Mesoporous Silica Nanoparticles (ABZ-M MCM-41): Loading albendazole into mesoporous silica structures increased cellular internalization, boosting tumor-killing potency by 2.9-fold compared to free albendazole in liver cancer cell lines.

• Polymeric Mixed Micelles: Formulations combining albendazole and paclitaxel inside folic acid/TPGS/Soluplus mixed micelles showed a sustained, controlled release over 90 hours and demonstrated superior synergistic toxicity in SKOV3 ovarian cancer cells.

3. Clinically Studied Cancer Entities

Through the aid of these advanced formulation strategies, repurposed albendazole is being actively translated and assessed across several major clinical oncological targets:

• Colorectal Cancer: Bypassing traditional therapy resistance by localized colonic release.

• Ovarian Cancer: Overcoming systemic administration barriers via nab-nanoparticles and intraperitoneal tumor target designs.

• Hepatocellular Carcinoma: Utilizing liver-selective uptake vectors (such as glucan or chitosan-lipid carriers) to concentrate the active drug directly inside hepatic lesions.

• Brain Tumors (Glioblastoma): Using lipid systems capable of crossing the blood-brain barrier to target aggressive, temozolomide-resistant cerebral tumors.

  ---

Drug Delivery and Repurposing Approaches for Albendazole Formulations

April 2026 7(1) DOI: 10.15212/bioi-2025-0045

https://www.researchgate.net/publication/403383298_Drug_Delivery_and_Repurposing_Approaches_for_Albendazole_Formulations

In translational medicine, we often view progress as a linear race to invent something entirely “new.” However, some of the most profound breakthroughs in oncology come from looking backward at the medicines already in our cabinets. This is drug repurposing—the scientific art of identifying new therapeutic applications for established, clinically approved drugs.

1. The Starting Point: Why We Look for Shortcuts

Developing a de novo drug is a monumental task often compared to finding a needle in a haystack—while the haystack is on fire and costs billions to search. Drug repurposing offers a strategic “shortcut” by leveraging our existing knowledge of a medicine’s safety profile.

The Inherent Advantages of Repurposing

For a patient, these advantages are the difference between waiting decades or months for a treatment:

• Proven Safety Profiles: Because these drugs are already FDA-approved, we have extensive longitudinal data on human toxicity and pharmacokinetics.

• Established Dosage Guidelines: Clinical educators and practitioners don’t have to start from zero; we already understand the human body’s tolerance levels.

• Accelerated Development: By bypassing early safety trials, we dramatically expedite the transition from the laboratory bench to the patient’s bedside.

Because traditional discovery is prohibitively slow and expensive, we must act as scientific detectives, using creative hypothesis generation to uncover the “hidden” cancer-fighting properties of established medicines.

2. Phase I: Generating the Hypothesis (The Spark)

How do we decide that a drug for alcoholism or arthritis might actually treat a tumor? The journey begins with a spark of data-driven logic.

The Three Stages of the Repurposing Journey

1. Hypothesis Generation: Identifying “core targets” of the disease and matching them to an existing drug’s profile.

2. Efficacy Testing: Validating that the drug works in controlled laboratory environments (in vitro and in vivo).

3. Clinical Trials: Moving directly into Phase II human trials once the safety data from the drug’s original use is confirmed.

Finding the Candidates

We utilize two primary methodologies to identify potential candidates:

3. Phase II: The Scientist’s Lab (The Tools of Discovery)

In this phase, we use advanced models to simulate the human body. Two of the most powerful tools in our arsenal are Tumoroids and Phenotypic Screening.

Tumoroids: The “Mini-Organs”

A tumoroid is a specialized type of cancer organoid—an in vitro 3D tissue grown from a patient’s own cells.

• Why they mimic real tumors:

  • Architecture: They grow in complex 3D structures rather than flat layers.

  • Genetic Profile: They retain the patient’s specific DNA mutations.

  • Mutational Landscape: They maintain the original tumor's biological diversity.

  • Therapeutic Response: They react to drugs with high fidelity to the patient’s actual clinical response.

Critical Thinking Note: As educators, we must recognize that while tumoroids are a massive leap forward, they currently lack vascularization and the complex Tumor Immune Microenvironment (TIME), such as immune and neural cells. They are a vital step toward patient reality, but not a full replacement.

Phenotypic Screening: Function-First

Rather than focusing on a single gene, scientists watch how a drug changes the cancer's “phenotype” (its physical behavior).

Case Study: Calcium Channel Blockers (CCBs) Originally indicated for hypertension and heart conditions, CCBs like Amlodipine, Felodipine, Dicloamanidipine, and Cilidipine underwent a phenotypic screen. Scientists found they inhibited filopodia formation—the “fingers” cancer cells use to crawl. This proved these heart drugs could physically prevent cancer cell invasion.

Once a tool proves a drug can work, we must map exactly where it attacks the cancer’s survival strategy.

4. Mapping the Target: The 14 Hallmarks of Cancer

Cancer is no longer viewed as a single disease, but a set of 14 updated hallmarks or survival behaviors. Repurposed drugs are chosen because they “flip the switch” on these specific behaviors.

Flipping the Switch: The Tumor Microenvironment (TME)

Cancer cells create “neighborhoods” (TMEs) that hide them from the immune system. We use repurposed drugs to disrupt these niches:

• Acidic Niche: Tumors are more acidic (pH 6.4–7) than healthy tissue. Proton Pump Inhibitors (PPIs) can neutralize this acidity, making chemotherapy more effective and preventing immune evasion.

• Hypoxic Microenvironment: Tumors thrive in low-oxygen zones. Ascorbic Acid (Vitamin C) has been shown to decrease the expression of HIF-1α, the protein that helps tumors survive without oxygen.

• Microbial Microenvironment: Gut bacteria can dictate treatment success. Inulin reshapes the gut’s “polymorphic microbiome,” boosting the immune system’s natural attack on the cancer.

While the lab results look promising, the journey from bench to bedside is fraught with practical obstacles.

5. Phase III: The Reality Check (Challenges & Clinical Trials)

Even a biologically “perfect” drug faces massive hurdles before it can be prescribed in an oncology ward.

Hurdles to Clinical Adoption

• Intellectual Property (IP) Rights:

  • Student Insight: When a drug is “off-patent,” pharmaceutical companies have little financial incentive to fund the $100M+ trials required for a new indication, even if the drug is highly effective.

• Dosage and Toxicity (The “Off-Target” Risk):

  • Student Insight: The dose required to kill a tumor may be much higher than the dose used for the drug’s original purpose. For example, using statins or metformin at oncology-level doses risks inducing severe hypolipidemia or hypoglycemia in patients.

• Regulatory Barriers:

  • Student Insight: Formal global guidance and incentives are currently lacking to help researchers navigate approval of “old” drugs for “new” life-saving roles.

Clinical Trial Spotlight

These drugs are currently undergoing the “reality check” of human testing:

• Metformin: Testing against Breast, Pancreas, and Prostate cancers.

• Statins: Testing against Gastric and Colorectal cancers.

• Celecoxib: Testing against Melanoma and postoperative Recurrent Gastric cancer.

These challenges are significant, but emerging delivery technologies like nanotechnology are helping us bypass dosage and toxicity limitations.

6. The Horizon: The Future of Repurposing

The future of this field lies in precision. We are no longer just finding the right drug; we are building better “delivery vehicles” for them.

Nanotechnology: Precision Topical Drug Delivery

Nanoparticles (liposomes, micelles, or metallic particles) act as microscopic envelopes that carry repurposed drugs directly to the tumor.

• The EPR Effect: We utilize the Enhanced Permeability and Retention (EPR) effect, where nanoparticles naturally accumulate in the “leaky” vasculature of tumor tissue while bypassing healthy cells.

• Reducing Side Effects: By “shielding” the drug until it reaches its target, we prevent it from accumulating in the kidneys or spleen, effectively lowering the systemic toxicity of high-dose treatments.

• Increasing Bioavailability: Many repurposed drugs (like Curcumin or Niclosamide) have poor water solubility; nanotechnology keeps them stable in the bloodstream until they reach the tumor site.

Final Insight: The Renaissance of Medicine

Drug repurposing represents a true “Renaissance” in medicine. It teaches us that the solutions to our most complex modern challenges might already be in our hands. By combining traditional medicinal wisdom, 20th-century pharmacology, and 21st-century nanotechnology, we are creating a more hopeful, faster, and more affordable future for cancer patients worldwide.

Drug repurposing for cancer therapy, April 2024

Signal Transduction and Targeted Therapy 9(1) DOI:10.1038/s41392-024-01808-1

https://www.researchgate.net/publication/379911710_Drug_repurposing_for_cancer_therapy

This was a sanctioned livestream with recordings hosted on Joe’s official blog.
Click here to watch the LiveStream Recording Question & Answer Session from
Thursday, August 20th at 2 pm CST

Topics covered in this session:

• Sourcing guidance

• Protocol updates

• Liver health Q&A — Questions from the audience about liver enzymes, with input from Joe and guest Keith Bishop (Prevail Over Cancer) on monitoring and general liver support

• Upcoming product — Adam mentioned Ultra Botanica’s liver support formula is in final development, expected to launch by end of August

• Pathway product breakdown

• Practitioner resources — Encouragement to loop in an integrative or functional medicine practitioner, and mention of Keith Bishop’s free consultation offer via prevailovercancer.com

• Audience questions — Wide-ranging Q&A covering general philosophy, and how to connect with the MyCancerStory.Rocks community

As always, none of the discussion in this session is medical advice — please direct any personal health questions to your own healthcare provider or an integrative practitioner.

Joe’s Blog- mycancerstory.rocks

Joe’s Facebook Group - https://www.facebook.com/groups/mycancerstoryrocks

1. The Hidden Potential in Your Medicine Cabinet

The landscape of modern oncology is defined by an increasingly unsustainable “Innovation Gap.” As demand for curative therapies grows, the traditional pharmaceutical pipeline remains a high-stakes gamble marked by astronomical costs and a staggering failure rate. For every breakthrough that reaches a patient, thousands of molecules vanish during clinical development, often due to unforeseen toxicity or lack of efficacy.

As a researcher and analyst, I see a strategic shortcut gaining momentum to bridge this gap: drug repurposing. Instead of engineering molecules from the ground up, researchers are auditing the existing pharmaceutical arsenal to uncover “off-target” effects that can dismantle cancer. Among the most compelling candidates are anthelmintics—medications traditionally used to treat parasitic infections. Could the same agents used for decades to treat deworming be the key to treating aggressive malignancies like pancreatic cancer and rare, treatment-resistant paragangliomas? I say yes. Recent research into benzimidazole-based compounds suggests that the answer is not only yes, but that these drugs may outperform conventional chemotherapy in ways we are only beginning to understand.

2. The 10-Year Shortcut: Why “Old” Drugs are High-Value Candidates

In drug development, time is as much a barrier as biology. Benzimidazole-based drugs, such as Mebendazole and Albendazole, are high-value candidates because they let researchers bypass the most treacherous hurdles of early-stage discovery. These compounds arrive with pre-verified safety profiles and decades of human pharmacokinetic data.

From an analyst’s perspective, the value proposition is clear: repurposing offers a regulatory fast track and significantly reduces R&D risk. However, the true innovation highlighted in recent studies isn’t just raiding the medicine cabinet—it involves technical refinement. Researchers have utilized patented salt formulations specifically designed to overcome the “poor aqueous solubility” that has historically limited the bioavailability of benzimidazoles. This chemical optimization transforms an old dewormer into a viable, high-potency systemic therapy.

As the source study highlights in its introduction:

“The discovery and development of new anticancer drugs... are tasks of a long, expensive and often challenging process that may fail throughout the clinical trial phases needed before drug approval.”

By leveraging already-approved products with these new salt formulations, we can shave years off the development timeline, offering a strategic path toward affordable, low-toxicity oncology.

3. Hope for the Untreatable: The Paraganglioma Breakthrough

One of the most striking findings in recent screenings is the efficacy of these compounds against paraganglioma—a rare, treatment-resistant tumor that often leaves clinicians with no viable options.

Benzimidazoles Tested on Paraganglioma for the First Time In a landmark breakthrough, researchers tested several benzimidazoles against PTJ64i and PTJ86i cell lines. Critically, these were patient-derived cell lines established directly from individuals with the disease, offering a high-fidelity model of how the drugs might perform in a clinical setting. The results were extraordinary: flubendazole and fenbendazole induced cell inhibition rates of up to 97%.

This discovery carries massive implications for “orphan designation.” For pharmaceutical innovators, obtaining orphan status for rare diseases like paraganglioma provides a strategic business advantage through market exclusivity. For patients, it represents a lifeline for “untreatable” conditions often overlooked by traditional R&D budgets.

4. Outsmarting Resistance: Avoiding the “Efflux Pump” Trap

A primary cause of chemotherapy failure is multi-drug resistance (MDR). Cancer cells are notorious for developing a defense mechanism known as P-gp (permeability glycoprotein)—a microscopic “efflux pump” that identifies and flushes out chemotherapy molecules before they can reach their targets.

Analysis of the pharmacokinetic parameters of benzimidazoles reveals a significant strategic advantage: flubendazole, parbendazole, oxibendazole, mebendazole, albendazole, and fenbendazole are not substrates for P-gp.

This “stealth” ability means these drugs are essentially invisible to the cell’s security system. While conventional treatments are being pumped out of the cell, these benzimidazoles remain inside, maintaining the concentrations necessary to trigger cell death. This makes them potentially superior to current chemotherapies in the context of resistant, aggressive tumors that have already learned to “reject” standard care.

5. The Power of the “Right Hand”: Why Chirality Changes Everything

In molecular science, “chirality” refers to molecules that are mirror images of one another—much like a right and left hand. While chemically identical, these “enantiomers” are processed differently by the human body. Precision at this level is the hallmark of modern clinical translation.

Researchers used high-performance liquid chromatography (HPLC) to isolate the (R) and (S) versions of certain benzimidazoles. They discovered that the (R)-enantiomers were drastically more potent. Furthermore, the (R)-form of ricobendazole has been observed to accumulate in the cerebrospinal fluid, suggesting a unique potential for treating brain metastases where other drugs fail to cross the blood-brain barrier.

The potency gap is most evident in pancreatic cancer cell lines (AsPC-1 and BxPC-3). The IC50 data (where a lower number indicates higher potency) tells the story:

• (R)-oxfendazole: 1.18 µM (AsPC-1) / 1.82 µM (BxPC-3)

• (S)-oxfendazole: >20 µM (Virtually inactive in both lines)

By selecting the “right-handed” version of the molecule, scientists can unlock a therapeutic power that the standard mixture simply cannot match.

6. More Than Just a One-Trick Pony: Unlocking “Polypharmacology”

Historically, benzimidazoles were thought to work solely by inhibiting tubulin (the cell’s structural skeleton). However, recent target prediction data reveals these drugs are “polypharmacological,” meaning they engage multiple biological targets simultaneously.

This multi-pronged attack is a massive advantage in oncology. Because these drugs hit several targets at once, it is significantly harder for a tumor to “mutate around” the treatment—a common cause of cancer recurrence. Key molecular targets identified include:

• MAPK14 (p38 alpha): A protein linked to shorter survival and advanced cancer stages.

• ABL1: A major regulator of cell growth and survival, often targeted in leukemias.

• VEGFR-2: A receptor that controls angiogenesis, the process by which a tumor builds its own blood supply.

By disrupting growth signals and simultaneously cutting off the tumor’s nutrient supply, these drugs offer a comprehensive assault on cancer’s infrastructure.

7. Conclusion: A Thought-Provoking Path Forward

The potential to repurpose benzimidazole anthelmintics into affordable, oral, low-toxicity cancer treatments represents more than a scientific curiosity—it is a move toward democratizing cancer care. By combining the low cost of “old” drugs with the high innovation of patented salt formulations and enantiomer precision, we can bypass the “Innovation Gap” and bring effective therapies to patients globally.

As we look for the next breakthrough in oncology, could the answer be hiding in the medicine we’ve already been using for decades?

Source:

Screening of Benzimidazole-Based Anthelmintics and Their Enantiomers as Repurposed Drug Candidates in Cancer Therapy

Pharmaceuticals 2021, 14, 372. https://doi.org/10.3390/ph14040372 Published: 17 April 2021, https://www.mdpi.com/1424-8247/14/4/372

Objective—Mebendazole and other anti-parasitic drugs are being used off-prescription based on social media and unofficial accounts of their anti-cancer activity. The purpose of this study was to conduct a controlled evaluation of mebendazole’s therapeutic efficacy in cell culture and in vivo models of ovarian cancer.

Epithelial ovarian cancer is the most lethal gynecologic cancer, largely because it has a high predilection for advanced-stage diagnosis (such as Stage 3C) and inevitably develops resistance to chemotherapy despite initially high response rates. While front-line chemotherapy regimens yield an initial remission rate of approximately 80%, fewer than 50% of patients survive past five years.

Current maintenance therapies used post-chemotherapy include bevacizumab (a VEGF-targeted angiogenesis inhibitor) and PARP inhibitors. Although these maintenance strategies prolong progression-free survival, they have a limited or uncertain impact on overall survival while imposing substantial toxicities, side effects, and financial expenses. Consequently, there is an urgent clinical need for novel, well-tolerated, and cost-effective maintenance therapies.

The Molecular Barrier: TP53 Mutations

A major bottleneck in treating ovarian cancer is that the vast majority of cases harbor TP53 null or missense mutations. In epithelial ovarian cancer, missense mutations frequently lead to a “gain-of-function” phenotype that actively drives resistance to chemotherapy-induced apoptosis.

This genetic landscape makes the anti-parasitic drug mebendazole (MBZ) a highly attractive candidate, as its primary anti-tumor mechanisms operate independently of functional p53.

Mebendazole’s Anti-Tumor Mechanisms in Ovarian Cancer

Controlled preclinical evaluations of mebendazole reveal that it is a potent inhibitor of ovarian cancer growth, utilizing a dual-action mechanism:

1. Tubulin Depolymerization: Mebendazole functions as a microtubule-destabilizing agent. It directly binds to and depolymerizes tubulin, disrupting the cellular microtubule network across various ovarian cancer cell lines.

2. p53-Independent p21 Induction: Rather than relying on p53 to activate cell cycle arrest, mebendazole significantly upregulates the cyclin-dependent kinase inhibitor p21 regardless of the cell’s p53 mutation status.

3. Intrinsic Apoptosis Activation: This multi-targeted disruption triggers the cleavages of initiator caspase-9, executioner caspase-3, and PARP-1, forcing aggressive ovarian cancer cells to undergo intrinsic apoptosis.

In vitro, mebendazole inhibits growth at nanomolar concentrations (IC50 values ranging from 400 nM to 1.7 μM) across a broad panel of ovarian cancer lines, including A2780 (p53 wild-type), SKOV3 (p53 null), ES2, MES-OV, and isogenic mutant sublines (SKOV3 R273H and R248W). It also significantly suppresses clonogenic survival and colony formation in these cell lines.

Overcoming Cisplatin Resistance In Vivo

To validate these findings in highly clinically relevant models, researchers evaluated mebendazole in patient-derived xenograft (PDX) models. These models (PDX-0003, which is p53 null, and PDX-0030, which is p53 positive/missense mutant) were derived directly from Stage 3C high-grade serous ovarian cancer patients with recurrent, platinum-resistant disease.

• Tumor Inhibition: Oral mebendazole (administered via oral gavage at 10, 25, or 50 mg/kg three times per week for three weeks) significantly inhibited tumor growth in both the p53 null and p53 missense mutant platinum-resistant PDX models.

• Dose-Responsive Efficacy: Mixed-effects analysis confirmed that mebendazole’s therapeutic efficacy was highly dose-responsive in both tumor models.

• Toxicity Profile: While the highest dose (50 mg/kg) caused a minor, transient reduction in mouse body weight (~5% weight loss, which is well below the 10% maximum tolerated threshold), histological analysis of liver and kidney tissue showed no evidence of systemic organ toxicity.

Preventing Recurrence: Mebendazole as Maintenance Therapy

Because prolonged maintenance therapy requires highly tolerable agents with minimal toxicity, researchers modeled post-chemotherapy maintenance by administering therapies before tumor establishment in an orthotopic intraperitoneal MES-OV (R282W p53 mutant) mouse model.

• Standalone Maintenance: Mebendazole monotherapy (50 mg/kg, adjusted to every other day to prevent initial weight loss) successfully prevented tumor establishment, yielding a 67% tumor-free rate compared to 0% in untreated controls.

• Synergy with PRIMA-1MET (APR-246): To enhance efficacy against missense mutant p53, mebendazole was combined with the mutant p53 reactivator PRIMA-1MET. In cell culture, this drug combination showed synergistic cytotoxicity and significantly increased intrinsic apoptosis.

• Maximizing Tumor-Free Rates: In the in vivo maintenance model, the combination of mebendazole and PRIMA-1MET achieved an outstanding 83% tumor-free rate. Additive logistic regression modeling confirmed that mebendazole was the primary driver associated with preventing tumor establishment.

These robust preclinical results provide a strong scientific rationale for initiating human clinical trials to evaluate mebendazole as a low-cost, low-toxicity maintenance therapy to prolong progression-free survival in ovarian cancer patients after failing platinum-based chemotherapies.

We evaluated the efficacy of combining mebendazole (MBZ) with the mutant p53 reactivator PRIMA-1MET (APR-246) in both in vivo maintenance models and in vitro assays, demonstrating a clear therapeutic advantage over either drug alone.

1. Prevention of Tumor Establishment (In Vivo Maintenance)

In an orthotopic intraperitoneal mouse model designed to simulate post-chemotherapy maintenance, the combination of mebendazole and PRIMA-1MET achieved the highest rate of preventing tumor establishment:

• Untreated Control: 0% tumor-free rate.

• PRIMA-1MET alone: 25% tumor-free rate.

• Mebendazole alone: 67% tumor-free rate.

• Combination Treatment: 83% tumor-free rate.

Statistical Nuances:

• Pairwise Superiority: Fisher’s exact test confirmed that the combination treatment was statistically more effective at preventing tumor growth than both the untreated control (p=0.015) and PRIMA-1MET alone (p=0.043).

• The Main Efficacy Driver: While the combination yielded the highest percentage (83%), an additive logistic regression model showed that mebendazole was the dominant driver of preventing tumor establishment (p=0.005, odds ratio = 27.535).

• No Detected Synergy In Vivo: At or under the doses tested in this animal model, the authors did not formally observe a statistically significant additive or synergistic interaction between the two drugs. The authors noted that further testing with varied dose combinations is needed to fully characterize potential in vivo synergy.

2. Synergistic Cytotoxicity (In Vitro)

Unlike the in vivo model, cell culture experiments demonstrated true pharmacological synergy across the board:

• Synergistic Interaction: Isobologram analyses yielded Combination Index (CI) values indicating clear synergistic interaction between mebendazole and PRIMA-1MET across all tested ovarian cancer cell lines, regardless of wild-type, missense-mutant, or null p53 profiles.

• Dose Reduction Advantage: Dose Reduction Index (DRI) values confirmed that combining the two agents allowed both mebendazole and PRIMA-1MET to be administered at significantly lower doses than would be required as single-drug treatments to achieve the same therapeutic effect.

3. Amplified Programmed Cell Death (Apoptosis)

The combination treatment was significantly more effective at driving cancer cells into programmed cell death:

• Greater Apoptotic Response: In cell culture, the combined regimen triggered significantly higher levels of intrinsic apoptosis than either drug alone.

• Enhanced Caspase Activation: This was verified by a substantial increase in the cleavage of initiator caspase-9, executioner caspase-3, and the DNA repair enzyme PARP-1.

Source:

Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer

PMID: 33131904, PMCID: PMC8820236, DOI: 10.1016/j.ygyno.2020.10.010

2021 Jan. doi: 10.1016/j.ygyno.2020.10.010. Epub 2020 Oct 31.

https://pubmed.ncbi.nlm.nih.gov/33131904/

Including some links:

To date, human clinical evidence for mebendazole includes completed case reports showing dramatic individual remissions, early-phase terminated monotherapy trials, and modern combination trials designed to exploit drug synergies.

Below is the chronological timeline of mebendazole’s human clinical history and active trials, mapped by target indication, drug combination, and trial milestones:

1. 2011: First Documented Adrenal Cancer Case Report

• Target Indication: Metastatic adrenocortical carcinoma.

• Dosing & Method: 100 mg twice daily (b.i.d.) orally (p.o.) as monotherapy.

• Adverse Effects: No significant adverse effects observed.

• Clinical Outcome: Marked regression of metastases. The patient’s disease stabilized successfully for 19 months, with disease progression only documented after 24 months of total therapy.

2. 2014: Refractory Metastatic Colon Cancer Case Report

• Target Indication: Refractory metastatic colorectal cancer.

• Dosing & Method: 100 mg twice daily (b.i.d.) orally (p.o.) as monotherapy for six weeks.

• Adverse Effects: Reversible hepatic enzyme elevation; AST and ALT increased up to five times above the normal limit.

• Clinical Outcome: Near-complete remission of metastases in the lungs and lymph nodes, alongside a good partial remission of metastases residing in the liver.

3. 2019: Terminated Phase 2a Gastrointestinal Trial (NCT03628079) [prematurely terminated because all participating patients experienced rapid disease progression.]

• Actual Completion Date: January 16, 2019.

• Patient Cohort: 11 patients.

• Target Indication: Advanced gastrointestinal cancer or cancer of unknown primary origin.

• Dosing & Method: Oral dose titration ranging from 50 mg to 4000 mg twice daily (b.i.d.) for 16 weeks.

• Clinical Outcome: Terminated early due to a lack of therapeutic effect. This failure highlighted that mebendazole may have weak efficacy when administered as a standalone monotherapy.

4. 2021: Completed Phase 1 Glioma Trial (NCT01729260)

• Actual Completion Date: April 16, 2021.

• Patient Cohort: 24 patients.

• Target Indication: High-grade glioma.

• Dosing & Method: Three times daily (t.i.d.) orally (p.o.) in a 28-day cycle.

• Combination Agent: Combined with standard temozolomide (TMZ) chemotherapy.

• Trial Goal: To determine the maximum tolerated dose of the mebendazole-TMZ combination.

5. 2022: Phase 1 Recurrent Pediatric Brain Cancer Trial (NCT02644291)

• Estimated Completion Date: June 2022.

• Patient Cohort: 21 patients (recruiting).

• Target Indication: Recurrent pediatric brain cancers.

• Dosing & Method: Three times daily (t.i.d.) orally (p.o.).

• Trial Goal: Safety evaluation and dose determination.

6. 2022: Advanced Hepatocellular Carcinoma Trial (NCT04443049)

• Estimated Completion Date: June 19, 2022.

• Patient Cohort: 170 patients (recruiting).

• Target Indication: Advanced hepatocellular carcinoma (HCC).

• Dosing & Method: 100 mg twice daily (b.i.d.) orally (p.o.).

• Combination Agent: Combined with standard-of-care lenvatinib.

7. 2023: Phase 1/2 Pediatric Glioma Trial (NCT01837862)

• Estimated Completion Date: April 2023.

• Patient Cohort: 36 patients (recruiting).

• Target Indication: Pediatric gliomas.

• Dosing & Method: Weight-based dosing of 50–200 mg/kg/day divided twice daily orally (p.o.).

• Combination Agent: Combined with standard anti-tumor drugs.

8. 2023: Phase 2 Incurable & Lethal Cancers Trial (NCT02366884)

• Estimated Completion Date: December 31, 2023.

• Patient Cohort: 250 patients (recruiting).

• Target Indication: Incurable and lethal advanced cancers.

• Dosing & Method: Tolerable, safe oral dosing for 10 to 12 months.

• Combination Agent: Combined within a multi-drug anti-protozoal therapeutic cocktail.

9. 2026: Phase 3 “METRICS” Cocktail Protocol Trial (NCT02201381)

• Estimated Completion Date: September 22, 2026.

• Patient Cohort: 207 patients (not yet recruiting at publication).

• Target Indication: Advanced solid tumors.

• Dosing & Method: 100 mg once daily (q.d.).

• Combination Agent: Evaluates mebendazole as part of a four-drug metabolic cocktail alongside atorvastatin, metformin, and doxycycline.

10. 2028: Phase 3 Colorectal Cancer Combination Trial (NCT03925662)

• Estimated Completion Date: December 2028.

• Patient Cohort: 40 patients (recruiting).

• Target Indication: Advanced colorectal cancer.

• Dosing & Method: Unspecified oral schedule.

• Combination Agent: Co-administered alongside standard FOLFOX chemotherapy and Avastin (bevacizumab).

Key Clinical Insights & Patterns Across Trials

• Brain Tumor Focus: Three out of the eight listed clinical trials specifically target brain tumors (gliomas and medulloblastomas). This focus is intentional, leveraging mebendazole’s proven ability to physicochemically penetrate the Blood-Brain Barrier (BBB) and reach therapeutic concentrations in central nervous system tissues.

• The Transition to Combinations: Modern Phase 3 trials have entirely abandoned mebendazole monotherapy. Because of low bioavailability and rapid clearance, modern protocols combine mebendazole with chemotherapy (FOLFOX), anti-angiogenics (Avastin), or metabolic agents (metformin/statins) to achieve synergistic, multi-pathway blockade.

The anti-tumor properties of benzimidazoles (BZs) are mediated through a broad, multi-targeted network of intracellular signaling cascades, bypassing the limitations of conventional single-node targeted therapies. Preclinical investigations have defined six primary mechanisms of action:

1. Disruption of Microtubule Dynamics: Similar to conventional tubulin-binding drugs, benzimidazoles bind specifically to (\beta)-tubulin to inhibit microtubule polymerization. This disrupts the mitotic spindle apparatus, leading to cell cycle arrest at the G2/M phase.

2. Induction of Programmed Cell Death (Apoptosis): BZs activate intrinsic, mitochondria-mediated apoptosis. They downregulate key negative regulators of p53, such as Mdm2 and MdmX, and trigger the cleavage of caspase-3, caspase-7, caspase-9, and PARP.

3. Inhibition of Angiogenesis and Metastasis: These agents block vascular endothelial growth factor (VEGF) secretion and hypoxia-inducible factor 1(\alpha) (HIF-1(\alpha)) to restrict tumor blood supply. They also inhibit tumor cell migration and block epithelial-to-mesenchymal transition (EMT).

4. Suppression of Cancer Stemness: BZs selectively target cancer stem-like cells (CSCs), which are notoriously resistant to conventional radiotherapy and chemotherapy, preventing tumor recurrence and self-renewal.

5. Induction of Autophagy: Emerging evidence indicates that BZs trigger autophagic cell death by acting as agonists for autophagy regulators (e.g., Atg4B) or upregulating lysosomal/endoplasmic reticulum proteins like EVA1A.

6. Metabolic Starvation: These dewormers impair glucose transport and downregulate glycolytic enzymes to starve highly metabolic tumor cells.

Selective Toxicity & In Vitro Efficacy Profiles

1. Albendazole (ABZ)

Albendazole exhibits potent growth inhibition across a wide array of cancers, including brain, breast, gastric, leukemia, colon, lung, ovarian, and skin malignancies. Notably, ABZ suppresses the growth of glioblastoma multiforme stem-like neurospheres at a highly potent half-maximal inhibitory concentration ((\text{IC}_{50})) of 0.1 (\mu\text{M}). It also selectively suppresses triple-negative breast cancer (TNBC) cells and KRAS-mutant lung cancer lines. When combined with radiation, ABZ acts as a radiosensitizer in lung and melanoma cells, causing double-strand DNA breaks and G2/M arrest.

2. Fenbendazole (FBZ)

Fenbendazole suppresses brain, breast, colorectal, lung, pancreatic, and melanoma cell lines. In lung cancer, FBZ is selectively cytotoxic against KRAS-mutant lines (compared to wild-type) by suppressing downstream RAS-related signaling pathways. Additionally, FBZ-induced apoptosis is p53-dependent; it shows significantly enhanced apoptotic activity in human non-small cell lung cancer (NSCLC) lines with wild-type p53 (A549, H460) compared to those harboring mutated p53 (H522).

3. Flubendazole (FLZ)

In a high-throughput screen of 321 cell lines across 26 cancer entities, flubendazole demonstrated remarkable selective toxicity toward hematological and pediatric malignancies:

• Highly Sensitive Entities: Multiple myeloma, neuroblastoma, and leukemia/lymphoma emerged as exceptionally sensitive to flubendazole, exhibiting a mean (\text{IC}_{90}) of <1 (\mu\text{M}). In neuroblastoma cell lines (e.g., UKF-NB-3), this cell death is driven by p53-mediated apoptosis.

• Breast Cancer and Trastuzumab Resistance: FLZ targets breast CSCs, decreasing CD44+/CD24- subpopulations and downregulating self-renewal genes (c-Myc, Oct4, Sox2, Nanog, and Cyclin D1). In HER2-positive breast cancer, FLZ overcomes trastuzumab resistance by downregulating key oncogenic signaling proteins (truncated p95HER2, phospho-HER2, phospho-HER3, and phospho-Akt) and physically preventing the hetero-dimerization of HER2 and HER3.

• STAT3 Inhibition in TNBC: In TNBC cell lines (MDA-MB-231, Hs578T, BT-549), flubendazole induces caspase-3/7 activation and apoptosis by directly blocking STAT3 phosphorylation.

• EVA1A-Mediated Autophagic Cell Death: FLZ binds directly to the Thr113 residue of Eva-1 homolog A (EVA1A). This upregulates EVA1A, promoting ATG5-dependent autophagy and triggering apoptotic cell death in TNBC.

• Castration-Resistant Prostate Cancer (CRPC): FLZ binds directly to p53 to improve its protein stability. Stabilized p53 binds to the promoter of SLC7A11, downregulating its expression alongside GPX4 to restrict cystine transport and trigger ferroptosis-mediated cell death.

• Melanoma Checkpoint Modulation: In melanoma lines (A-375, BOWES, RPMI-7951), flubendazole disrupts microtubules to cause abnormal mitosis and multinucleated giant cells. Systemically, it suppresses tumor growth and metastasis by downregulating PD-1 expression (independent of PD-L1) in cancer cells and decreasing local myeloid-derived suppressor cell (MDSC) accumulation.

• Senescence & EMT Blockade: In colorectal lines, FLZ shifts the cell cycle (decreasing cyclin D1, increasing cyclin B1) and induces cellular senescence (indicated by elevated SA-(\beta)-galactosidase). In oral squamous cell cancer (OSCC), it blocks cellular migration and TGF-(\beta)-induced EMT by suppressing N-cadherin and downregulating migration-related proteins (FAK, Rho-A, Rac1, and GEF-H1).

4. Mebendazole (MBZ)

Mebendazole inhibits a wide range of aggressive cell lines (including brain, TNBC, AML, and head and neck cancers). Notably, its growth-inhibitory effect on head and neck squamous cell carcinoma (HNSCC) is more potent than the standard chemotherapy cisplatin. MBZ also targets chemoresistance directly by downregulating multiple drug resistance (MDR) gene transporters (ABCB1, ABCC1, and SLC47A1), preventing drug efflux in malignant cells. Computational modeling has identified MBZ as a potent inhibitor of TRAF2- and NCK-interacting kinase (TNIK), blocking the Wnt/(\beta)-catenin pathway to restrict colorectal cancer.

5. Other Benzimidazoles

• Nocodazole (NCZ) & Parbendazole (PBZ): These exhibit some of the lowest (\text{IC}_{50}) values in colorectal cancer lines (RKO, HCT-116). NCZ induces a higher rate of tubulin depolymerization and abnormal spindle formation in NSCLC cells than mebendazole. Both NCZ and PBZ overcome chemotherapeutic resistance by disrupting the ERK-1/2-dependent HSF1 pathway.

• Oxfendazole (OFZ): Inhibits NSCLC cell lines (A549, H1299) by suppressing oncogenic c-Src activation; its antiproliferative effect is highly synergistic when combined with cisplatin.

• Oxibendazole (OBZ): Suppresses prostate, colon, pancreatic, and skin cancer lines by upregulating the tumor suppressors p53 and microRNA (miRNA)-204.

In Vivo Anti-Tumor Validation in Animal Models

         [ HIGH-VOLUME IN VIVO BENZIMIDAZOLE VALIDATION ]

     Glioma, NSCLC, TNBC        Ovarian Ascites (OVCAR-3)     Hepatocellular, HNSCC, AML
     [ABZ, MBZ, FLZ, OBZ]             [ABZ, MBZ]                     [MBZ, FLZ]
              │                            │                             │
              ▼                            │                             ▼
  ┌────────────────────────┐               │                 ┌────────────────────────┐
  │  Significant Delay in  │               ▼                 │ Outstanding Regression │
  │  Solid Tumor Growth &  │    ┌────────────────────┐       │  and Improvement in   │
  │   Vessel Angiogenesis  │    │  Inhibition of VEGF│       │  Organ Histopathology  │
  └────────────────────────┘    │  Shuts Down Fluid  │       └────────────────────────┘
                                │  Ascites Formation │
                                └────────────────────┘

• Albendazole (ABZ): In vivo efficacy has been validated in rodent glioma (GL261), NSCLC (A549), and TNBC (MDA-MB-231) xenografts. In ovarian cancer (OVCAR-3) models, ABZ does not significantly shrink solid tumor mass, but it completely shuts down malignant ascites accumulation by potently inhibiting VEGF expression and tumor angiogenesis.

• Fenbendazole (FBZ): Due to regulatory restrictions limiting FBZ primarily to veterinary use, in vivo oncology data are limited. However, in A549 lung adenocarcinoma xenografts in mice, oral FBZ at 1 mg/mouse every other day for 12 days successfully induced apoptosis, reduced tumor vascularity, and delayed growth.

• Flubendazole (FLZ): FLZ has demonstrated robust in vivo activity in brain, breast, colorectal, hematological, and skin cancer models. In chorioallantoic membrane (CAM) assay grafts, FLZ treatment significantly suppressed neuroblastoma growth and vascular development. It also dramatically delays tumor growth in both wild-type TNBC and trastuzumab-resistant HER2-positive breast cancer xenografts.

• Mebendazole (MBZ): MBZ is the most heavily validated in vivo agent, demonstrating efficacy against intracranial brain tumors (medulloblastoma and glioblastoma), TNBC, HNSCC, and chemoresistant leukemias. In murine hepatocellular carcinoma, oral MBZ achieved outstanding tumor regression while markedly improving liver histology and clinical function. It also serves as a potent chemopreventative agent; in APCMin/+ mice (a familial adenomatous polyposis model), oral MBZ successfully reduced colorectal polyp count and microadenoma formation.

Translational Bottlenecks: Why Lab Efficacy Often Outpaces the Clinic

Despite these overwhelming preclinical breakthroughs, human clinical trials have yielded relatively modest results. This translational gap is driven by two primary biopharmaceutical challenges:

1. Extreme Entity and Compound Dependency: The efficacy of benzimidazoles is highly specific to the combination of the individual dewormer and the genetic profile of the cancer cell line. For instance, screens show that MBZ is highly superior against melanoma, MTZ and FBZ are best against KRAS-mutant lung cancer, and OBZ/MBZ perform best in colon cancer. Historically, human clinical trials have suffered because they recruited general “solid tumor” cohorts without screening for these highly susceptible genetic sub-types.

2. The Pharmacokinetic Barrier: Benzimidazoles are highly hydrophobic and poorly water-soluble, resulting in extremely poor oral bioavailability (1% to 5% for albendazole, and 5% to 10% for mebendazole). In humans, a standard 400 mg oral dose of ABZ yields an active metabolite concentration ((C_{max})) of only 0.047 to 0.1 (\mu\text{M}), and a massive 2 g dose of flubendazole results in a plasma concentration of less than 0.016 (\mu\text{M}). These levels are far below the standard in vitro inhibitory concentrations ((\text{IC}_{50}) values) of 1 to 5 (\mu\text{M}) required to kill most cancer cell lines. Furthermore, rapid hepatic clearance (ABZ’s active half-life is less than 1.5 hours) prevents the drug from sustaining therapeutic blood levels.

To bridge this clinical gap, modern research focuses on developing novel drug delivery systems (such as amorphous solid dispersions, nanoparticle carriers, or cyclodextrin inclusion complexes) to dramatically increase water solubility, systemic absorption, and half-life in human patients.

Fenbendazole (FBZ) is classified as a highly hydrophobic, poorly water-soluble drug, which results in exceptionally low oral bioavailability and limits its therapeutic performance. To overcome this biopharmaceutical hurdle, research has focused on preparing pharmaceutical cocrystals to dramatically enhance its solubility and dissolution rate.

Here are the source details for the synthesis, characterization, and performance of these novel formulations:

1. The Method: Liquid-Assisted Grinding (LAG)

To synthesize these cocrystals, researchers utilized the Liquid-Assisted Grinding (LAG) technique. Equimolar quantities of pure fenbendazole and specific carboxylic acid conformers (coformers) were ground together in a mortar and pestle at room temperature, using methanol added dropwise as a catalytic solvent. The resulting mass was then dried and evaporated.

The three primary coformers tested were:

• Salicylic acid

• Benzoic acid

• Cinnamic acid

2. Aqueous Solubility Enhancement

Saturation solubility testing in an aqueous medium over 24 hours revealed substantial improvements when comparing the prepared cocrystals to the pure, unmodified drug:

• Pure Fenbendazole: Exhibited a baseline aqueous solubility of 0.21 mg/ml.

• Fenbendazole-Cinnamic Acid: Increased solubility to 0.845 mg/ml.

• Fenbendazole-Benzoic Acid: Increased solubility to 0.985 mg/ml.

• Fenbendazole-Salicylic Acid: Achieved the highest solubility at 1.052 mg/ml.

While the mathematical difference between 1.052 mg/ml and 0.21 mg/ml represents a ~5-fold increase, the researchers state that these synthesized cocrystals demonstrated a 3-fold to 5-fold improvement in aqueous solubility over the pure API.

3. Accelerated In Vitro Dissolution

The improvement in saturation solubility directly translated to faster, more complete drug release during in vitro dissolution experiments (conducted in a buffer at 37 ºC):

• At 15 Minutes: The Fenbendazole-Salicylic acid cocrystal achieved a 38% cumulative drug release, compared to just 22% for the pure drug.

• At 1 Hour: While the pure drug reached an 81% release, the salicylic acid cocrystal achieved 100% complete drug release in under an hour. This rapid release dramatically increases the drug's active surface area available for physiological absorption.

4. Underlying Hydrogen-Bonding Mechanism

The creation of these stable, highly soluble neutral crystalline structures is driven by specific intermolecular interactions:

• Hydrogen Bonding: Structural characterization indicates that fenbendazole and the pharmaceutical coformers engage via strong hydrogen bonds. Specifically, the -NH group of the donor (fenbendazole) binds to the oxygen atoms of the acceptor (the carboxylic acid conformers).

• Novel Crystalline Phase: Differential Scanning Calorimetry (DSC) thermograms of the cocrystals showed a single, sharp melting endotherm at a distinct position from both pure fenbendazole and the free coformers, confirming a unique crystalline phase.

Optimizing Fenbendazole Solubility via Salicylic Acid Cocrystallization

The salicylic acid coformer performed best among the three organic acids tested.

Performance Metrics:

Aqueous Solubility: The fenbendazole-salicylic acid cocrystal achieved the highest saturation solubility of 1.052 mg/ml (compared to 0.985 mg/ml for benzoic acid, 0.845 mg/ml for cinnamic acid, and just 0.21 mg/ml for the pure drug). This represents a 50-fold improvement in aqueous solubility over the unmodified drug.

In Vitro Dissolution: It reached a 38% cumulative drug release within 15 minutes (compared to 22% for the pure drug) and achieved 100% complete drug release in under one hour, whereas the pure drug only reached 81% release in the same timeframe.

Because of these outstanding solubility and dissolution results, the researchers concluded that salicylic acid is the preferred coformer for producing advanced, high-bioavailability fenbendazole formulations.

Source:

COCRYSTALS OF FENBENDAZOLE WITH ENHANCED IN VITRO DISSOLUTION PERFORMANCE

Accepted: 15/06/23 Doi: 10.31838/ecb/2023.12.Si8.826

https://www.researchgate.net/publication/376685019_COCRYSTALS_OF_FENBENDAZOLE_WITH_ENHANCED_IN_VITRO_DISSOLUTION_PERFORMANCE